{"parse":{"title":"Theralizumab","pageid":4402358,"revid":860060983,"text":{"*":"<div class=\"mw-parser-output\"><table class=\"infobox\" style=\"width:22em;border-spacing:2px;\"><caption><span title=\"International nonproprietary name (INN): Theralizumab\">Theralizumab</span></caption><tbody><tr><th colspan=\"2\" style=\"text-align:center;background:#ddd\"><a href=\"/wiki/Monoclonal_antibody\" title=\"Monoclonal antibody\">Monoclonal antibody</a></th></tr><tr><th scope=\"row\" style=\"padding:0.2em 0; line-height:1.2em;\"><a href=\"/wiki/File:Engineered_monoclonal_antibodies.svg\" title=\"File:Engineered monoclonal antibodies.svg\">Type</a></th><td>\nWhole antibody</td></tr><tr><th scope=\"row\" style=\"padding:0.2em 0; line-height:1.2em;\"><a href=\"/wiki/Monoclonal_antibody#Production\" title=\"Monoclonal antibody\">Source</a></th><td>\n<a href=\"/wiki/Humanized\" class=\"mw-redirect\" title=\"Humanized\">Humanized</a> (from <a href=\"/wiki/Mouse\" title=\"Mouse\">mouse</a>)</td></tr><tr><th scope=\"row\" style=\"padding:0.2em 0; line-height:1.2em;\"><a href=\"/wiki/Antigen\" title=\"Antigen\">Target</a></th><td>\n<a href=\"/wiki/CD28\" title=\"CD28\">CD28</a></td></tr><tr><th colspan=\"2\" style=\"text-align:center;background:#ddd\">Clinical data</th></tr><tr><th scope=\"row\" style=\"padding:0.2em 0; line-height:1.2em;\"><a href=\"/wiki/Route_of_administration\" title=\"Route of administration\">Routes of<br />administration</a></th><td>\n<a href=\"/wiki/Intravenous\" class=\"mw-redirect\" title=\"Intravenous\">intravenous</a></td></tr><tr><th scope=\"row\" style=\"padding:0.2em 0; line-height:1.2em;\"><a href=\"/wiki/Anatomical_Therapeutic_Chemical_Classification_System\" title=\"Anatomical Therapeutic Chemical Classification System\">ATC code</a></th><td>\n<div class=\"plainlist\"><ul><li>none</li></ul></div></td></tr><tr><th colspan=\"2\" style=\"text-align:center;background:#ddd\">Legal status</th></tr><tr><th scope=\"row\" style=\"padding:0.2em 0; line-height:1.2em;\"><a href=\"/wiki/Regulation_of_therapeutic_goods\" title=\"Regulation of therapeutic goods\">Legal status</a></th><td>\n<div class=\"plainlist\">\n<ul><li>terminated</li></ul></div>\n</td></tr><tr><th colspan=\"2\" style=\"text-align:center;background:#ddd\">Identifiers</th></tr><tr><th scope=\"row\" style=\"padding:0.2em 0; line-height:1.2em;\"><a href=\"/wiki/ChemSpider\" title=\"ChemSpider\">ChemSpider</a></th><td>\n<div class=\"plainlist\"><ul><li>none</li></ul></div></td></tr><tr><th colspan=\"2\" style=\"text-align:center;background:#ddd\"><span style=\"font-weight:normal;\">&#160;&#160;<span class=\"reflink plainlinks nourlexpansion\"><a class=\"external text\" href=\"//en.wikipedia.org/w/index.php?title=Special:ComparePages&amp;rev1=448717516&amp;page2=Theralizumab\">(verify)</a></span></span></th></tr></tbody></table>\n<p><b>Theralizumab</b> (also known as <b>TGN1412</b>, <b>CD28-SuperMAB</b>, and <b>TAB08</b>) is an <a href=\"/wiki/Immunomodulator\" class=\"mw-redirect\" title=\"Immunomodulator\">immunomodulatory</a> drug developed by Professor Thomas H\u00fcnig of the <a href=\"/wiki/University_of_W%C3%BCrzburg\" title=\"University of W\u00fcrzburg\">University of W\u00fcrzburg</a>.\n</p><p>It was withdrawn from development after inducing severe inflammatory reactions in the <a href=\"/wiki/Phases_of_clinical_research#Phase_I\" title=\"Phases of clinical research\">first-in-human study</a> by <a href=\"/wiki/PAREXEL\" title=\"PAREXEL\">PAREXEL</a> in London in March 2006.<sup id=\"cite_ref-1\" class=\"reference\"><a href=\"#cite_note-1\">&#91;1&#93;</a></sup> The developing company, TeGenero Immuno Therapeutics, went bankrupt later that year.\n</p><p>The commercial rights were then acquired by a Russian startup, <a href=\"/w/index.php?title=TheraMAB&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"TheraMAB (page does not exist)\">TheraMAB</a>.<sup id=\"cite_ref-2\" class=\"reference\"><a href=\"#cite_note-2\">&#91;2&#93;</a></sup> The drug was renamed TAB08. Phase I and II clinical trials have been completed for arthritis<sup id=\"cite_ref-3\" class=\"reference\"><a href=\"#cite_note-3\">&#91;3&#93;</a></sup> and clinical trials have been initiated for cancer.\n</p><p>Originally intended for the treatment of <a href=\"/wiki/B_cell\" title=\"B cell\">B cell</a> <a href=\"/wiki/Chronic_lymphocytic_leukemia\" title=\"Chronic lymphocytic leukemia\">chronic lymphocytic leukemia</a> (B-CLL) and <a href=\"/wiki/Rheumatoid_arthritis\" title=\"Rheumatoid arthritis\">rheumatoid arthritis</a>,<sup id=\"cite_ref-TeGenero2006-02-20_4-0\" class=\"reference\"><a href=\"#cite_note-TeGenero2006-02-20-4\">&#91;4&#93;</a></sup> TGN1412 is a <a href=\"/wiki/Humanized_antibody\" title=\"Humanized antibody\">humanised monoclonal antibody</a> that not only binds to, but is a strong <a href=\"/wiki/Agonist\" title=\"Agonist\">agonist</a> for, the <a href=\"/wiki/CD28\" title=\"CD28\">CD28</a> receptor of the <a href=\"/wiki/Immune_system\" title=\"Immune system\">immune system</a>'s <a href=\"/wiki/T_cell\" title=\"T cell\">T cells</a>.<sup id=\"cite_ref-Lin2004_5-0\" class=\"reference\"><a href=\"#cite_note-Lin2004-5\">&#91;5&#93;</a></sup>  CD28 is the co-receptor for the T cell receptor; It binds to receptors on the interacting partner in the reaction through one of its ligands (<a href=\"/wiki/B7_family\" class=\"mw-redirect\" title=\"B7 family\">B7 family</a>).\n</p><p>In its first human <a href=\"/wiki/Clinical_trial\" title=\"Clinical trial\">clinical trials</a>, it caused catastrophic systemic organ failures in the subjects, despite being administered at a supposed sub-clinical dose of 0.1&#160;mg per kg; some 500 times lower than the dose found safe in animals.<sup id=\"cite_ref-NewScientist2006-08-17_6-0\" class=\"reference\"><a href=\"#cite_note-NewScientist2006-08-17-6\">&#91;6&#93;</a></sup> Six volunteers were hospitalized on 13 March 2006, at least four of these suffering from <a href=\"/wiki/Multiple_organ_dysfunction_syndrome\" title=\"Multiple organ dysfunction syndrome\">multiple organ dysfunction</a>. Tentative opinions from an as-yet uncompleted inquiry suggest that the problems resulted from \"unforeseen biological action in humans\", rather than breach of trial protocols, and the case therefore has had important ramifications for future trials of potentially powerful clinical agents.\n</p><p>Scientists in early 2007 put forth the theory that the drug acted in a different fashion in humans as compared with the laboratory animals in which the drug was first tried.  The severe reactions in humans could have only occurred, they believe, in those with <a href=\"/wiki/Memory_T_cell\" title=\"Memory T cell\">memory T lymphocytes</a>.  Animals raised in a sterile lab would presumably have no 'memory' of previous illnesses, thus would not exhibit the severe reactions that occurred in the human subjects.<sup id=\"cite_ref-7\" class=\"reference\"><a href=\"#cite_note-7\">&#91;7&#93;</a></sup>  However this is a misunderstanding of the research: the research says that lab animals studied have fewer memory T cells than humans, and that stimulation through the CD28 receptor alone in memory T cells causes them to infiltrate organs and also activates them.<sup id=\"cite_ref-mirenda_8-0\" class=\"reference\"><a href=\"#cite_note-mirenda-8\">&#91;8&#93;</a></sup>\n</p><p>The drug, which was designated as an <a href=\"/wiki/Orphan_drug\" title=\"Orphan drug\">orphan medical product</a> by the <a href=\"/wiki/European_Medicines_Agency\" title=\"European Medicines Agency\">European Medicines Agency</a> in March 2005, was developed by TeGenero Immuno Therapeutics, tested by <a href=\"/wiki/Parexel\" class=\"mw-redirect\" title=\"Parexel\">Parexel</a> and manufactured by <a href=\"/wiki/Boehringer-Ingelheim\" class=\"mw-redirect\" title=\"Boehringer-Ingelheim\">Boehringer-Ingelheim</a>.<sup id=\"cite_ref-TeGenero2005-03-13_9-0\" class=\"reference\"><a href=\"#cite_note-TeGenero2005-03-13-9\">&#91;9&#93;</a></sup><sup id=\"cite_ref-TeGenero2003-11-17_10-0\" class=\"reference\"><a href=\"#cite_note-TeGenero2003-11-17-10\">&#91;10&#93;</a></sup> TeGenero announced the first elucidation of the molecular structure of CD28 almost exactly one year prior to commencement of the TGN1412 phase I clinical trial.\n</p>\n<div id=\"toc\" class=\"toc\"><input type=\"checkbox\" role=\"button\" id=\"toctogglecheckbox\" class=\"toctogglecheckbox\" style=\"display:none\" /><div class=\"toctitle\" lang=\"en\" dir=\"ltr\"><h2>Contents</h2><span class=\"toctogglespan\"><label class=\"toctogglelabel\" for=\"toctogglecheckbox\"></label></span></div>\n<ul>\n<li class=\"toclevel-1 tocsection-1\"><a href=\"#Description_of_the_drug\"><span class=\"tocnumber\">1</span> <span class=\"toctext\">Description of the drug</span></a></li>\n<li class=\"toclevel-1 tocsection-2\"><a href=\"#Mechanism_of_action\"><span class=\"tocnumber\">2</span> <span class=\"toctext\">Mechanism of action</span></a></li>\n<li class=\"toclevel-1 tocsection-3\"><a href=\"#Clinical_trials\"><span class=\"tocnumber\">3</span> <span class=\"toctext\">Clinical trials</span></a></li>\n<li class=\"toclevel-1 tocsection-4\"><a href=\"#Criticism_and_controversy\"><span class=\"tocnumber\">4</span> <span class=\"toctext\">Criticism and controversy</span></a></li>\n<li class=\"toclevel-1 tocsection-5\"><a href=\"#Medicines_and_Healthcare_products_Regulatory_Agency_view\"><span class=\"tocnumber\">5</span> <span class=\"toctext\">Medicines and Healthcare products Regulatory Agency view</span></a></li>\n<li class=\"toclevel-1 tocsection-6\"><a href=\"#Follow_up_publications\"><span class=\"tocnumber\">6</span> <span class=\"toctext\">Follow up publications</span></a></li>\n<li class=\"toclevel-1 tocsection-7\"><a href=\"#See_also\"><span class=\"tocnumber\">7</span> <span class=\"toctext\">See also</span></a></li>\n<li class=\"toclevel-1 tocsection-8\"><a href=\"#References\"><span class=\"tocnumber\">8</span> <span class=\"toctext\">References</span></a></li>\n<li class=\"toclevel-1 tocsection-9\"><a href=\"#External_links\"><span class=\"tocnumber\">9</span> <span class=\"toctext\">External links</span></a></li>\n</ul>\n</div>\n\n<h2><span class=\"mw-headline\" id=\"Description_of_the_drug\">Description of the drug</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Theralizumab&amp;action=edit&amp;section=1\" title=\"Edit section: Description of the drug\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Mice of the inbred strain BALB/c were immunized with recombinant human CD28-Fc fusion proteins and boosted with a B lymphoma cell line transfected to express human CD28.  Hybridomas were obtained by fusing B cells with the hybridoma partner X63Ag8.653 and screened for reactivity with human CD28 and TCR-independent mitogenic activity.  Two monoclonals called 5.11A1 and 9D7 were identified. The more active of the two, 5.11A1, is a mouse IgG1 immunoglobulin.\n</p><p>The <a href=\"/wiki/Complementarity_determining_region\" class=\"mw-redirect\" title=\"Complementarity determining region\">complementarity determining regions</a> of 5.11A1 were cloned into the framework of human IgG and combined with IgG1 (TGN1112) or IgG4 (TGN1412) constant regions. According to the company's Investigator Brochure, \"TGN1412 is a humanised monoclonal antibody directed against the human CD28 antigen.  The molecule was genetically engineered by transfer of the complementarity determining regions (CDRs) from heavy and light chain variable region sequences of a monoclonal mouse anti-humanC28 [sic]  antibody (5.11A1, Luhder et al., 2003) into human heavy and light chain variable frameworks.  Humanised variable regions were subsequently recombined with a human gene coding for the IgG4 gamma chain and with a human gene coding for a human kappa chain, respectively.\"<sup id=\"cite_ref-11\" class=\"reference\"><a href=\"#cite_note-11\">&#91;11&#93;</a></sup>\n</p><p>The recombinant genes were transfected into <a href=\"/wiki/Chinese_hamster_ovary_cell\" title=\"Chinese hamster ovary cell\">Chinese hamster ovary cells</a> and the recombinant antibody harvested from culture supernatant.\n</p>\n<h2><span class=\"mw-headline\" id=\"Mechanism_of_action\">Mechanism of action</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Theralizumab&amp;action=edit&amp;section=2\" title=\"Edit section: Mechanism of action\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div class=\"thumb tright\"><div class=\"thumbinner\" style=\"width:252px;\"><a href=\"/wiki/File:T_cell_activation.svg\" class=\"image\"><img alt=\"\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/d/db/T_cell_activation.svg/250px-T_cell_activation.svg.png\" width=\"250\" height=\"378\" class=\"thumbimage\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/d/db/T_cell_activation.svg/375px-T_cell_activation.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/d/db/T_cell_activation.svg/500px-T_cell_activation.svg.png 2x\" data-file-width=\"328\" data-file-height=\"496\" /></a>  <div class=\"thumbcaption\"><div class=\"magnify\"><a href=\"/wiki/File:T_cell_activation.svg\" class=\"internal\" title=\"Enlarge\"></a></div>T lymphocyte activation pathway is triggered when a T cell encounters its cognate antigen, coupled to an MHC molecule, on the surface of an infected cell or a phagocyte.</div></div></div>\n<p><a href=\"/wiki/T_cell#Activation\" title=\"T cell\">Activation of T cells</a> normally requires both engagement of the <a href=\"/wiki/T_cell_receptor\" class=\"mw-redirect\" title=\"T cell receptor\">antigen receptor</a> (signal 1) and <a href=\"/wiki/Co-stimulation\" title=\"Co-stimulation\">co-stimulation</a> (signal 2). Studies of monoclonal antibodies specific for mouse, rat, or human CD28 identified so-called \"superagonistic\" antibodies that could stimulate T cells without concurrent antigen-receptor stimulation (signal 1). Whether this activity represents a stronger activity or a different activity is uncertain.\n</p><p>Two antibodies specific for human CD28 were identified. The more active of the two, TGN1112 (originally called 5.11A1), belonged to the IgG1 class of immunoglobulins. The other, TGN1412 (clone 9D7), belonged to the IgG4 class. The TCR-independent agonism of these antibodies involved binding to a specific part of the CD28 molecule called the C\"D loop.<sup id=\"cite_ref-Luhder2003_12-0\" class=\"reference\"><a href=\"#cite_note-Luhder2003-12\">&#91;12&#93;</a></sup> \nIt was initially hypothesized that an antibody with this property could be therapeutically useful in stimulating the immune system in <a href=\"/wiki/Immunosuppression\" title=\"Immunosuppression\">immunosuppressed</a> patients. However, <i><a href=\"/wiki/In_vitro\" title=\"In vitro\">in vitro</a></i> and <i><a href=\"/wiki/In_vivo\" title=\"In vivo\">in vivo</a></i> data from animal studies later suggested that administration would lead to preferential activation of <a href=\"/wiki/Regulatory_T_cell\" title=\"Regulatory T cell\">regulatory T cells</a>, leading to a net effect of T-cell downregulation. On its website, the company wrote: \"A pronounced T-cell activation and expansion mediated by CD28-SuperMAB in animal models is accompanied by the expression of anti-inflammatory <a href=\"/wiki/Cytokine\" title=\"Cytokine\">cytokines</a>, like IL-10, rather than by the severe <a href=\"/wiki/Cytokine_release_syndrome\" title=\"Cytokine release syndrome\">cytokine release syndrome</a> of pro-inflammatory mediators induced by other agents that address the TCR complex.\".<sup id=\"cite_ref-TeGenero2006-02-20_4-1\" class=\"reference\"><a href=\"#cite_note-TeGenero2006-02-20-4\">&#91;4&#93;</a></sup>  As it turned out, the results of the first trial in humans indicate that this may not always be the case.\n</p><p>A new explanation for the trial mishap was suggested by the findings of a recent paper in <i>Clinical Immunology</i>. Pillai <i>et al.</i> found that all T cells that get activated using conventional TCR-mediated stimulation become regulatory for a brief time and express FOXP3. However, eventually most of these cells downregulate their regulatory capabilities and become <a href=\"/wiki/Plasma_cell\" title=\"Plasma cell\">effector cells</a>. Thus, attempts to induce FOXP3+ T cells might also induce effector cells capable of causing tissue damage.<sup id=\"cite_ref-13\" class=\"reference\"><a href=\"#cite_note-13\">&#91;13&#93;</a></sup>\n</p><p>Other cells activated by CD28 ligation in humans are <a href=\"/wiki/Eosinophil_granulocyte\" class=\"mw-redirect\" title=\"Eosinophil granulocyte\">eosinophil granulocytes</a>. They can release IFN-\u03b3, IL-2, IL-4, and IL-13.<sup id=\"cite_ref-14\" class=\"reference\"><a href=\"#cite_note-14\">&#91;14&#93;</a></sup><sup id=\"cite_ref-15\" class=\"reference\"><a href=\"#cite_note-15\">&#91;15&#93;</a></sup> However, most <i>in vitro</i> experiments are limited to the use of purified peripheral blood mononuclear cells (PBMN's) that do not contain those cells.\n</p><p>To function as an agonist, it has been suggested that TGN1412 needs to be a whole <a href=\"/wiki/Antibody\" title=\"Antibody\">antibody</a>, including the constant (Fc) region. According to a report by TeGenero, the F(ab)2 is not able to generate the required stimulation.<sup id=\"cite_ref-16\" class=\"reference\"><a href=\"#cite_note-16\">&#91;16&#93;</a></sup> Unlike the related clone TGN1112, an IgG1, TGN1412 is of the subclass IgG4. This choice was made as TGN1112 showed antibody-dependent cellular cytotoxicity on CD28+ Jurkat cells. Thus the function of antibody binding via an Fc\u03b3 receptor seems to be a requirement for the immune regulation. However, cell <a href=\"/wiki/Opsonisation\" class=\"mw-redirect\" title=\"Opsonisation\">opsonisation</a> by antibody leads normally to <a href=\"/wiki/Phagocytosis\" title=\"Phagocytosis\">phagocytosis</a> of the labeled cells, as seen in the case of <a href=\"/wiki/HIV\" title=\"HIV\">HIV</a>.<sup id=\"cite_ref-17\" class=\"reference\"><a href=\"#cite_note-17\">&#91;17&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Clinical_trials\">Clinical trials</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Theralizumab&amp;action=edit&amp;section=3\" title=\"Edit section: Clinical trials\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>The <a href=\"/wiki/Phases_of_clinical_research#Phase_I\" title=\"Phases of clinical research\">Phase I</a> <a href=\"/wiki/Clinical_trial\" title=\"Clinical trial\">clinical trials</a>  were conducted by Parexel at an independent clinical trials unit in leased space on the premises of <a href=\"/wiki/Northwick_Park_and_St._Mark%27s_Hospital\" class=\"mw-redirect\" title=\"Northwick Park and St. Mark&#39;s Hospital\">Northwick Park and St. Mark's Hospital</a>, <a href=\"/wiki/London\" title=\"London\">London</a>, on 13 March 2006.<sup id=\"cite_ref-Parexel2005-03-15_18-0\" class=\"reference\"><a href=\"#cite_note-Parexel2005-03-15-18\">&#91;18&#93;</a></sup><sup id=\"cite_ref-njem_19-0\" class=\"reference\"><a href=\"#cite_note-njem-19\">&#91;19&#93;</a></sup>  Parexel is a company that carries out drug trials on behalf of pharmaceutical and biotechnology companies. Healthy volunteers were recruited to the study with a \u00a32,000 fee, reportedly much higher than the 'few hundred quid' offered for other medical tests in the region. The trial resulted in hospitalization of all six volunteers administered the drug, at least four of whom suffered <a href=\"/wiki/Multiple_organ_dysfunction_syndrome\" title=\"Multiple organ dysfunction syndrome\">multiple organ dysfunction</a>.<sup id=\"cite_ref-BBC2006-03-18_20-0\" class=\"reference\"><a href=\"#cite_note-BBC2006-03-18-20\">&#91;20&#93;</a></sup>\nThe payment was reported by newspapers. For most trials, payments are in the range of around \u00a31,000 per week - but the 'few hundred quid' trials mentioned above are those which the general public are most familiar with (since they only last a day or two, do not require working individuals to take time off work, and hence are more common).<sup class=\"noprint Inline-Template Template-Fact\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Citation_needed\" title=\"Wikipedia:Citation needed\"><span title=\"This claim needs references to reliable sources. (August 2011)\">citation needed</span></a></i>&#93;</sup>\nThe trial was a double-blind, randomized, <a href=\"/wiki/Placebo-controlled_studies\" class=\"mw-redirect\" title=\"Placebo-controlled studies\">placebo-controlled study</a>, with two of the eight subjects receiving a <a href=\"/wiki/Placebo\" title=\"Placebo\">placebo</a>, and six receiving 1/500th of the highest dose used in previous experiments with <a href=\"/wiki/Crab-eating_Macaque\" class=\"mw-redirect\" title=\"Crab-eating Macaque\">cynomolgus macaques</a>. All six of the trial subjects who received the drug were male, aged 19 to 34 (median 29.5); none had a notable medical history, and all were well in the 2 weeks before the trial.<sup id=\"cite_ref-njem_19-1\" class=\"reference\"><a href=\"#cite_note-njem-19\">&#91;19&#93;</a></sup>  The drug was given by intravenous infusion, starting at 8am, with an interval of around 10 minutes between patients, and each infusion lasting from 3 to 6 minutes.<sup id=\"cite_ref-njem_19-2\" class=\"reference\"><a href=\"#cite_note-njem-19\">&#91;19&#93;</a></sup>  Roughly five minutes after the last participant had received his dose, the participant who had received the first dose complained of headache, and soon afterwards fever and pain. He took his shirt off, complaining that he felt like he was burning. Shortly after, the remaining participants who received the actual drug also became ill, vomiting and complaining of severe pain. The first patient was transferred to the Northwick Park hospital's intensive care unit 12 hours after infusion, with the others following within the next 4 hours.<sup id=\"cite_ref-njem_19-3\" class=\"reference\"><a href=\"#cite_note-njem-19\">&#91;19&#93;</a></sup>  A severely affected volunteer, Mohammed Abdalla, a 28-year-old who said he had hoped to set his brother up in business in Egypt, was described as having suffered a ballooned head.  This led to his description as being similar to the \"<a href=\"/wiki/Joseph_Merrick\" title=\"Joseph Merrick\">Elephant Man</a>\".  A volunteer also lost his fingers and toes as a result of being injected with the drug.<sup id=\"cite_ref-21\" class=\"reference\"><a href=\"#cite_note-21\">&#91;21&#93;</a></sup>\n</p><p>All of the men were reported to have experienced severe <a href=\"/wiki/Cytokine_release_syndrome\" title=\"Cytokine release syndrome\">cytokine release syndrome</a> resulting in <a href=\"/wiki/Angioedema\" title=\"Angioedema\">angioedema</a>, swelling of <a href=\"/wiki/Skin\" title=\"Skin\">skin</a> and <a href=\"/wiki/Mucous_membrane\" title=\"Mucous membrane\">mucous membranes</a>, akin to the effects of the complement cascade in severe allergic reaction. The patients were treated with <a href=\"/wiki/Corticosteroid\" title=\"Corticosteroid\">corticosteroids</a> to reduce inflammation, and <a href=\"/wiki/Plasmapheresis\" title=\"Plasmapheresis\">plasma-exchange</a> to attempt to remove TGN1412 from their circulation.  Paradoxically, the men's white blood cells had vanished almost completely several hours after administration of TGN1412.<sup id=\"cite_ref-NewScientist2006-08-17_6-1\" class=\"reference\"><a href=\"#cite_note-NewScientist2006-08-17-6\">&#91;6&#93;</a></sup>\n</p><p>According to a press release from 5 July 2006 on the North West London Hospitals NHS Trust website, where the men were treated, the patients continued to improve and \"five of them went home within a month of the incident, while one patient remained in hospital until 26 June, when he also went home.\"<sup id=\"cite_ref-22\" class=\"reference\"><a href=\"#cite_note-22\">&#91;22&#93;</a></sup> However, Head of pharmacology at University College London Trevor Smart has suggested that the men may never fully recover, and may suffer long-term disruption to their immune systems.\n</p><p>TGN1412 had not previously been given to humans (although a single patient in Northampton had been given a similar drug and had a similar reaction, according to the report after the events); however, the trial was preceded by animal testing, including in <a href=\"/wiki/Primate\" title=\"Primate\">non-human primates</a><sup class=\"noprint Inline-Template Template-Fact\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Citation_needed\" title=\"Wikipedia:Citation needed\"><span title=\"This claim needs references to reliable sources. (May 2016)\">citation needed</span></a></i>&#93;</sup>. The company claims that these did not indicate any safety issues. The US patent application states \"it could be shown in a pilot study that an <a href=\"/wiki/In_vitro\" title=\"In vitro\">in vitro</a> administration of anti-human CD28-SuperMAB induces in a rhesus monkey <a href=\"/wiki/In_vivo\" title=\"In vivo\">in vivo</a> a profound activation of T cells, without clinically visible side effects\" and goes on to say \"This antibody\u2014in spite of its strong T cell-stimulatory properties\u2014is very well tolerated in vivo, in contrast to all other known <a href=\"/wiki/T_cell\" title=\"T cell\">T cell</a> activating substances.\"<sup id=\"cite_ref-USpatent_23-0\" class=\"reference\"><a href=\"#cite_note-USpatent-23\">&#91;23&#93;</a></sup>\n</p>\n<div class=\"thumb tright\"><div class=\"thumbinner\" style=\"width:252px;\"><a href=\"/wiki/File:CD28_structure.gif\" class=\"image\"><img alt=\"\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/8/81/CD28_structure.gif/250px-CD28_structure.gif\" width=\"250\" height=\"188\" class=\"thumbimage\" srcset=\"//upload.wikimedia.org/wikipedia/commons/8/81/CD28_structure.gif 1.5x\" data-file-width=\"300\" data-file-height=\"225\" /></a>  <div class=\"thumbcaption\"><div class=\"magnify\"><a href=\"/wiki/File:CD28_structure.gif\" class=\"internal\" title=\"Enlarge\"></a></div>Structure of human CD28.</div></div></div>\n<p><a href=\"/wiki/TeGenero\" class=\"mw-redirect\" title=\"TeGenero\">TeGenero</a> has apologized to the families involved, insists that these effects were completely unexpected, and said that all protocols have been followed. An investigation by the UK drug regulator reported that the reaction was not due to contamination of the dose, or an incorrect dose being administered, but suggested that the problem was due to \"on target\" effects of the drug. Criticism has been raised that six participants were given the drug in such a short time, which is against the recommendations of standard literature. Despite this, the <a href=\"/wiki/Medicines_and_Healthcare_products_Regulatory_Agency\" title=\"Medicines and Healthcare products Regulatory Agency\">Medicines and Healthcare products Regulatory Agency</a> (MHRA) has confirmed that they had approved the trial, including the protocol of giving the dose to all men within a short time. It appears the MHRA approved a protocol involving the doses being administered between 8.00h-10.00h (i.e., 2 hours). One of the placebo-receiving participants has explained the doses were given with 2-minute intervals. Even though the participants were dosed with short intervals, this is not a deviation from the approved protocol.\n</p><p>The MHRA has further stated that the initial dose of TGN1412 was intended to be the first of a course of injections, with the dosage being ramped up over time.  It has been reported that the initial dose was one five-hundredth of that which the animal studies indicated was a maximum safe dose.<sup id=\"cite_ref-ft2006-03-16_24-0\" class=\"reference\"><a href=\"#cite_note-ft2006-03-16-24\">&#91;24&#93;</a></sup>  Dr. David Glover, an industry consultant, has suggested that because the antibody was raised against <i>human</i> CD28, the safe dosage may have been lower in humans than in animals.<sup id=\"cite_ref-Reuters2006-03-19_25-0\" class=\"reference\"><a href=\"#cite_note-Reuters2006-03-19-25\">&#91;25&#93;</a></sup> More concerningly, it has been shown that even using information available prior to the human first dose, it can be shown that the size of the initial dose was too high. Predictions showed that the 0.1&#160;mg starting dose would bind to 86 to 91% of all CD28 receptors in the body,<sup id=\"cite_ref-26\" class=\"reference\"><a href=\"#cite_note-26\">&#91;26&#93;</a></sup> which means that even at the minimum starting dose selected, the investigators would anticipate seeing the maximum effect of the drug.\n</p>\n<h2><span class=\"mw-headline\" id=\"Criticism_and_controversy\">Criticism and controversy</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Theralizumab&amp;action=edit&amp;section=4\" title=\"Edit section: Criticism and controversy\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>As of March 2006, there appear to have been two issues. There was the issue of the trial protocol of giving the drug to six participants within a short time. While the MHRA had approved a two-hour protocol, the drug was administered to all participants within just twenty minutes, based on the statement of a study participant.<sup class=\"noprint Inline-Template Template-Fact\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Citation_needed\" title=\"Wikipedia:Citation needed\"><span title=\"This claim needs references to reliable sources. (November 2017)\">citation needed</span></a></i>&#93;</sup> Neither the companies involved nor the authorities have commented on that point. Another issue was whether the company should have anticipated that the drug would provoke this reaction in humans. The comments on the company webpage and in the patent application indicated that the company knew that this type of drug could cause a severe <a href=\"/wiki/Cytokine_release_syndrome\" title=\"Cytokine release syndrome\">cytokine release syndrome</a>. An immunologist contacted by <i><a href=\"/wiki/New_Scientist\" title=\"New Scientist\">New Scientist</a></i> and who wished to be anonymous has commented that \"You don\u2019t need to be a rocket scientist to work out what will happen if you non-specifically activate every T cell in the body.\"<sup id=\"cite_ref-newscientist20060317_27-0\" class=\"reference\"><a href=\"#cite_note-newscientist20060317-27\">&#91;27&#93;</a></sup>\n</p><p>While the drug had appeared to be safe in animal models, researchers noted that there were reasons why these may not be indicative of the response in humans, particularly with respect to this type of drug.<sup id=\"cite_ref-telegraph20060317_28-0\" class=\"reference\"><a href=\"#cite_note-telegraph20060317-28\">&#91;28&#93;</a></sup> \nThe BBC reported that \"two of 20 monkeys used in earlier tests suffered an increase in the size of <a href=\"/wiki/Lymph_node\" title=\"Lymph node\">lymph nodes</a>,\" but that \"this information was given to the men and submitted to the test regulators.\"<sup id=\"cite_ref-bbc20060320_29-0\" class=\"reference\"><a href=\"#cite_note-bbc20060320-29\">&#91;29&#93;</a></sup> \nTeGenero said this was transient and was evidence of the extra T cells that the drug produces.<sup id=\"cite_ref-tegenero20060319_30-0\" class=\"reference\"><a href=\"#cite_note-tegenero20060319-30\">&#91;30&#93;</a></sup> \nExperiments with another drug affecting the CD28 receptor (but to a lesser extent than TGN1412) had also shown side effects in human trials.<sup id=\"cite_ref-nature20060317_31-0\" class=\"reference\"><a href=\"#cite_note-nature20060317-31\">&#91;31&#93;</a></sup> \nThere have been criticisms that the risks taken and the design of the protocol were insufficiently justified by proper <a href=\"/wiki/Statistics\" title=\"Statistics\">statistical evidence</a>.<sup id=\"cite_ref-rss2007_32-0\" class=\"reference\"><a href=\"#cite_note-rss2007-32\">&#91;32&#93;</a></sup>\n</p><p>Critics of animal testing have cited the case to argue that experiments on nonhuman animals, even in species closely related to humans, are not necessarily predictive of human responses, and cannot justify the harm inflicted on animals or the resultant risks to humans.<sup id=\"cite_ref-Akhtar_2014_33-0\" class=\"reference\"><a href=\"#cite_note-Akhtar_2014-33\">&#91;33&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Medicines_and_Healthcare_products_Regulatory_Agency_view\">Medicines and Healthcare products Regulatory Agency view</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Theralizumab&amp;action=edit&amp;section=5\" title=\"Edit section: Medicines and Healthcare products Regulatory Agency view\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>The Medicines and Healthcare products Regulatory Agency (MHRA) issued an interim report on the TGN1412 trial on 5 April 2006, followed by a final report on 25 May 2006.<sup id=\"cite_ref-MHRA20060405_34-0\" class=\"reference\"><a href=\"#cite_note-MHRA20060405-34\">&#91;34&#93;</a></sup><sup id=\"cite_ref-35\" class=\"reference\"><a href=\"#cite_note-35\">&#91;35&#93;</a></sup> \nIt found no deficiencies in TeGenero's pre-clinical work and no evidence of undisclosed studies. Parexel's records and processes appeared in order, including dose measurement and administration, and no deficiencies were found that may have led to contamination or overdose. The MHRA felt that their actions did not contribute to the serious adverse events. \nGerman regulatory authorities inspected the production of the material by Boehringer Ingelheim, looking at the manufacture, testing, storage and distribution of the TGN1412, but found no deficiencies were identified which could have contributed to the serious adverse effects.\n</p><p>The MHRA concluded that the most likely cause of the reaction in trial subjects was an unpredicted biological action of the drug in humans. The UK <a href=\"/wiki/Secretary_of_State_for_Health\" class=\"mw-redirect\" title=\"Secretary of State for Health\">Secretary of State for Health</a> agreed to establish a group of leading international experts to consider those issues and to provide a report on the future authorisation of such trials with an interim report at three months, with <a href=\"/wiki/Gordon_Duff\" title=\"Gordon Duff\">Gordon Duff</a>, Professor of Molecular Medicine at <a href=\"/wiki/Sheffield_University\" class=\"mw-redirect\" title=\"Sheffield University\">Sheffield University</a>, as Chair of the group. Until the expert group report, all further clinical trial applications involving first-in-humans trials of any monoclonal antibody or other novel molecules targeting the immune system were not to be authorised in the UK.<sup id=\"cite_ref-36\" class=\"reference\"><a href=\"#cite_note-36\">&#91;36&#93;</a></sup>\n</p><p>In December 2006, the final report of the Expert Group on Phase One Clinical Trials was published.<sup id=\"cite_ref-37\" class=\"reference\"><a href=\"#cite_note-37\">&#91;37&#93;</a></sup> It found that the trial had not considered what constituted a safe dose in humans, and that then-current law had not required it. It made 22 recommendations, including the need for independent expert advice before a high-risk study was allowed, testing only one volunteer at a time (sequential inclusion of participants) in case there were rapid ill effects, and administering drugs slowly by infusion rather than as an injection.<sup id=\"cite_ref-38\" class=\"reference\"><a href=\"#cite_note-38\">&#91;38&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Follow_up_publications\">Follow up publications</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Theralizumab&amp;action=edit&amp;section=6\" title=\"Edit section: Follow up publications\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>The trial has become subject of several academic publications:\n</p><p>Immunologists from the German Federal Agency for Sera and Vaccines, the <a href=\"/wiki/Paul_Ehrlich_Institute\" title=\"Paul Ehrlich Institute\">Paul Ehrlich Institute</a> pointed out in 2007 that the predictive value of pre-clinical animal models required reevaluation, dose fixing needed refinement or redesign, criteria for high-risk antibodies needed to be established, and pre-Phase I studies were needed where a dose was calculated with a pre-clinical No-effect level instead of the <a href=\"/wiki/No-observed-adverse-effect_level\" title=\"No-observed-adverse-effect level\">No-observed-adverse-effect level</a>. The newly established  European clinical trials database (<a href=\"/wiki/EudraCT\" title=\"EudraCT\">EudraCT</a> Database) might be helpful.<sup id=\"cite_ref-39\" class=\"reference\"><a href=\"#cite_note-39\">&#91;39&#93;</a></sup>\n</p><p>The UK <a href=\"/wiki/National_Institute_for_Biological_Standards_and_Control\" title=\"National Institute for Biological Standards and Control\">National Institute for Biological Standards and Control</a> wrote in 2009 a near-maximum immuno-stimulatory dose had been given, because a safe starting dose in man had been calculated \"based upon results from pre-clinical safety testing in a non-responsive species\". It reported that the European guidelines for first-in-man phase-I clinical trials of biologics had been revised.<sup id=\"cite_ref-40\" class=\"reference\"><a href=\"#cite_note-40\">&#91;40&#93;</a></sup>\n</p><p>In 2010, the failure to predict a severe <a href=\"/wiki/Cytokine_release_syndrome\" title=\"Cytokine release syndrome\">cytokine release syndrome</a> in humans was explained with in vitro data of the CD4+ effector memory T-cells of <i><a href=\"/wiki/Macaca_fascicularis\" class=\"mw-redirect\" title=\"Macaca fascicularis\">Macaca fascicularis</a></i>, the species of primate used for pre-clinical safety testing of TGN1412, lacking CD28 expression.<sup id=\"cite_ref-41\" class=\"reference\"><a href=\"#cite_note-41\">&#91;41&#93;</a></sup>\n</p><p>In 2013 it was described how standard pro-inflammatory markers TNF\u03b1 and IL-8 did not predict the proinflammatory response (gave a false negative result) but that IL-2 release and lymphoproliferation were helpful,<sup id=\"cite_ref-42\" class=\"reference\"><a href=\"#cite_note-42\">&#91;42&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"See_also\">See also</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Theralizumab&amp;action=edit&amp;section=7\" title=\"Edit section: See also\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div>\n\n&#32;\n<table class=\"multicol\" role=\"presentation\" style=\"border-collapse: collapse; padding: 0; border: 0; background:transparent; width:100%;\"><tbody><tr>\n<td style=\"text-align: left; vertical-align: top;\">\n<ul><li><a href=\"/wiki/Adverse_effect_(medicine)\" class=\"mw-redirect\" title=\"Adverse effect (medicine)\">Adverse effect (medicine)</a></li>\n<li><a href=\"/wiki/Clinical_trial_protocol\" class=\"mw-redirect\" title=\"Clinical trial protocol\">Clinical trial protocol</a></li>\n<li><a href=\"/wiki/Pharmacovigilance\" title=\"Pharmacovigilance\">Pharmacovigilance</a></li>\n<li><a href=\"/wiki/BIA_10-2474\" title=\"BIA 10-2474\">BIA 10-2474</a></li></ul>\n<p>&#32;\n</p>\n</td>\n<td style=\"text-align: left; vertical-align: top;\">\n<ul><li><a href=\"/wiki/Co-stimulation\" title=\"Co-stimulation\">Co-stimulation</a></li>\n<li><a href=\"/wiki/Drug_development\" title=\"Drug development\">Drug development</a></li>\n<li><a href=\"/wiki/Pre-clinical_development\" title=\"Pre-clinical development\">Pre-clinical development</a></li>\n<li><a href=\"/wiki/EudraVigilance\" title=\"EudraVigilance\">EudraVigilance</a></li></ul>\n<p>&#32;\n</p>\n</td></tr></tbody></table></div>\n<h2><span class=\"mw-headline\" id=\"References\">References</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Theralizumab&amp;action=edit&amp;section=8\" title=\"Edit section: References\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div class=\"reflist columns references-column-width\" style=\"-moz-column-width: 30em; -webkit-column-width: 30em; column-width: 30em; list-style-type: decimal;\">\n<ol class=\"references\">\n<li id=\"cite_note-1\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-1\">^</a></b></span> <span class=\"reference-text\"><a href=\"/wiki/Ben_Goldacre\" title=\"Ben Goldacre\">Goldacre, Ben</a>. <i><a href=\"/wiki/Bad_Pharma\" title=\"Bad Pharma\">Bad Pharma</a></i>. Fourth Estate, 2012, pp. 8\u201310, 104\u2013105.</span>\n</li>\n<li id=\"cite_note-2\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-2\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external free\" href=\"https://www.reuters.com/article/us-drug-comeback-exclusive/exclusive-drug-that-caused-elephant-man-side-effect-makes-comeback-after-2006-disaster-idUSKBN0MK1SQ20150324\">https://www.reuters.com/article/us-drug-comeback-exclusive/exclusive-drug-that-caused-elephant-man-side-effect-makes-comeback-after-2006-disaster-idUSKBN0MK1SQ20150324</a></span>\n</li>\n<li id=\"cite_note-3\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-3\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external free\" href=\"https://clinicaltrials.gov/ct2/show/study/NCT01990157\">https://clinicaltrials.gov/ct2/show/study/NCT01990157</a></span>\n</li>\n<li id=\"cite_note-TeGenero2006-02-20-4\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-TeGenero2006-02-20_4-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-TeGenero2006-02-20_4-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\">TeGenero (2006-02-20). <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20060412052458/http://www.tegenero.com/research__development/drug_development/index.php\">\"Drug Development\"</a>. TeGenero. Archived from <a rel=\"nofollow\" class=\"external text\" href=\"http://www.tegenero.com/research__development/drug_development/index.php\">the original</a> on 12 April 2006<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2006-03-16</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Drug+Development&amp;rft.pub=TeGenero&amp;rft.date=2006-02-20&amp;rft.au=TeGenero&amp;rft_id=http%3A%2F%2Fwww.tegenero.com%2Fresearch&#95;_development%2Fdrug_development%2Findex.php&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ATheralizumab\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Lin2004-5\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-Lin2004_5-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Chia-Huey Lin; Thomas Kerkau; Christine Guntermann; Martin Trischler; Niklas Beyersdorf; Yvonne Scheuring; Hans-Peter Tony; Christian Kneitz; Martin Wilhelm; Peter Mueller; Thomas Huenig; Thomas Hanke (2004-11-16). <a rel=\"nofollow\" class=\"external text\" href=\"http://meeting.bloodjournal.org/cgi/content/abstract/104/11/2519\">\"Superagonistic Anti-CD28 Antibody TGN1412 as a Potential Immunotherapeutic for the Treatment of B Cell Chronic Lymphocytic Leukemia\"</a>. <i><a href=\"/wiki/Blood_(journal)\" title=\"Blood (journal)\">Blood</a> (ASH Annual Meeting Abstracts)</i>. <b>104</b> (11): Abstract 2519.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Blood+%28ASH+Annual+Meeting+Abstracts%29&amp;rft.atitle=Superagonistic+Anti-CD28+Antibody+TGN1412+as+a+Potential+Immunotherapeutic+for+the+Treatment+of+B+Cell+Chronic+Lymphocytic+Leukemia&amp;rft.volume=104&amp;rft.issue=11&amp;rft.pages=Abstract+2519&amp;rft.date=2004-11-16&amp;rft.au=Chia-Huey+Lin&amp;rft.au=Thomas+Kerkau&amp;rft.au=Christine+Guntermann&amp;rft.au=Martin+Trischler&amp;rft.au=Niklas+Beyersdorf&amp;rft.au=Yvonne+Scheuring&amp;rft.au=Hans-Peter+Tony&amp;rft.au=Christian+Kneitz&amp;rft.au=Martin+Wilhelm&amp;rft.au=Peter+Mueller&amp;rft.au=Thomas+Huenig&amp;rft.au=Thomas+Hanke&amp;rft_id=http%3A%2F%2Fmeeting.bloodjournal.org%2Fcgi%2Fcontent%2Fabstract%2F104%2F11%2F2519&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ATheralizumab\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-NewScientist2006-08-17-6\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-NewScientist2006-08-17_6-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-NewScientist2006-08-17_6-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation news\">Andy Coghlan (2006-08-14). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.newscientist.com/article/dn9734-mystery-over-drug-trial-debacle-deepens/\">\"Mystery over drug trial debacle deepens\"</a>. <i>New Scientist</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2006-08-14</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=New+Scientist&amp;rft.atitle=Mystery+over+drug+trial+debacle+deepens&amp;rft.date=2006-08-14&amp;rft.au=Andy+Coghlan&amp;rft_id=https%3A%2F%2Fwww.newscientist.com%2Farticle%2Fdn9734-mystery-over-drug-trial-debacle-deepens%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ATheralizumab\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-7\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-7\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\">Fleming, Nic (2008-04-12). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.telegraph.co.uk/news/uknews/1540591/Study-claims-to-solve-drug-trial-mystery.html\">\"Study claims to solve drug trial mystery\"</a>. <i>The Daily Telegraph</i>. London<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2010-05-25</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Daily+Telegraph&amp;rft.atitle=Study+claims+to+solve+drug+trial+mystery&amp;rft.date=2008-04-12&amp;rft.aulast=Fleming&amp;rft.aufirst=Nic&amp;rft_id=https%3A%2F%2Fwww.telegraph.co.uk%2Fnews%2Fuknews%2F1540591%2FStudy-claims-to-solve-drug-trial-mystery.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ATheralizumab\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-mirenda-8\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-mirenda_8-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Mirenda, Vincenzo;  et al. (1 April 2007). <a rel=\"nofollow\" class=\"external text\" href=\"http://bloodjournal.hematologylibrary.org/cgi/content/full/109/7/2968%7C\">\"Physiologic and aberrant regulation of memory T-cell trafficking by the costimulatory molecule CD28\"</a>. <i>Blood</i>. <b>109</b> (7): 2968\u20132977. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1182/blood-2006-10-050724\">10.1182/blood-2006-10-050724</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/17119120\">17119120</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Blood&amp;rft.atitle=Physiologic+and+aberrant+regulation+of+memory+T-cell+trafficking+by+the+costimulatory+molecule+CD28&amp;rft.volume=109&amp;rft.issue=7&amp;rft.pages=2968-2977&amp;rft.date=2007-04-01&amp;rft_id=info%3Adoi%2F10.1182%2Fblood-2006-10-050724&amp;rft_id=info%3Apmid%2F17119120&amp;rft.aulast=Mirenda&amp;rft.aufirst=Vincenzo&amp;rft_id=http%3A%2F%2Fbloodjournal.hematologylibrary.org%2Fcgi%2Fcontent%2Ffull%2F109%2F7%2F2968%257C&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ATheralizumab\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-TeGenero2005-03-13-9\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-TeGenero2005-03-13_9-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation pressrelease\"><a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20060319033931/http://www.tegenero.com/documents/pr_tegenero_march_11_2005.pdf\">\"TeGenero AG receives EU-orphan drug designation for Humanized Agonistic Anti-CD28 Monoclonal Antibody TGN1412 for the treatment of B-cell Chronic Lymphocytic Leukaemia, B-CLL\"</a> <span style=\"font-size:85%;\">(PDF)</span> (Press release). TeGenero. 13 March 2005. Archived from <a rel=\"nofollow\" class=\"external text\" href=\"http://www.tegenero.com/documents/pr_tegenero_march_11_2005.pdf\">the original</a> <span style=\"font-size:85%;\">(PDF)</span> on 19 March 2006.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=TeGenero+AG+receives+EU-orphan+drug+designation+for+Humanized+Agonistic+Anti-CD28+Monoclonal+Antibody+TGN1412+for+the+treatment+of+B-cell+Chronic+Lymphocytic+Leukaemia%2C+B-CLL&amp;rft.pub=TeGenero&amp;rft.date=2005-03-13&amp;rft_id=http%3A%2F%2Fwww.tegenero.com%2Fdocuments%2Fpr_tegenero_march_11_2005.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ATheralizumab\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-TeGenero2003-11-17-10\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-TeGenero2003-11-17_10-0\">^</a></b></span> <span class=\"reference-text\">\n<cite class=\"citation pressrelease\"><a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20060318205642/http://tegenero.com/documents/2003_11_tg005_pressrelease_e.pdf\">\"Boehringer Ingelheim and TeGenero sign agreement to develop and manufacture CD28-SuperMAB\"</a> <span style=\"font-size:85%;\">(PDF)</span> (Press release). TeGenero. 17 November 2003. Archived from <a rel=\"nofollow\" class=\"external text\" href=\"http://www.tegenero.com/documents/2003_11_tg005_pressrelease_e.pdf\">the original</a> <span style=\"font-size:85%;\">(PDF)</span> on 18 March 2006.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Boehringer+Ingelheim+and+TeGenero+sign+agreement+to+develop+and+manufacture+CD28-SuperMAB&amp;rft.pub=TeGenero&amp;rft.date=2003-11-17&amp;rft_id=http%3A%2F%2Fwww.tegenero.com%2Fdocuments%2F2003_11_tg005_pressrelease_e.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ATheralizumab\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-11\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-11\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.circare.org/foia5/tgn1412investigatorbrochure.pdf\">Investigator's Brochure</a>, Circare.org, 19 December 2005</span>\n</li>\n<li id=\"cite_note-Luhder2003-12\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-Luhder2003_12-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Luhder F, Huang Y, Dennehy KM, Guntermann C, Muller I, Winkler E, Kerkau T, Ikemizu S, Davis SJ, Hanke T, Hunig T (2003). <a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC2193880\">\"Topological Requirements and Signaling Properties of T Cell\u2013activating, Anti-CD28 Antibody Superagonists\"</a>. <i>J Exp Med</i>. <b>197</b> (8): 955&#8211;66. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1084/jem.20021024\">10.1084/jem.20021024</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC2193880\">2193880</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/12707299\">12707299</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J+Exp+Med&amp;rft.atitle=Topological+Requirements+and+Signaling+Properties+of+T+Cell%E2%80%93activating%2C+Anti-CD28+Antibody+Superagonists&amp;rft.volume=197&amp;rft.issue=8&amp;rft.pages=955-66&amp;rft.date=2003&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2193880&amp;rft_id=info%3Apmid%2F12707299&amp;rft_id=info%3Adoi%2F10.1084%2Fjem.20021024&amp;rft.aulast=Luhder&amp;rft.aufirst=F&amp;rft.au=Huang%2C+Y&amp;rft.au=Dennehy%2C+KM&amp;rft.au=Guntermann%2C+C&amp;rft.au=Muller%2C+I&amp;rft.au=Winkler%2C+E&amp;rft.au=Kerkau%2C+T&amp;rft.au=Ikemizu%2C+S&amp;rft.au=Davis%2C+SJ&amp;rft.au=Hanke%2C+T&amp;rft.au=Hunig%2C+T&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2193880&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ATheralizumab\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-13\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-13\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC1868523\">\"Transient regulatory T-cells: A state attained by all activated human T-cells\"</a>. <i>Clinical Immunology</i>. <b>123</b>: 18\u201329. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1016/j.clim.2006.10.014\">10.1016/j.clim.2006.10.014</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC1868523\">1868523</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Clinical+Immunology&amp;rft.atitle=Transient+regulatory+T-cells%3A+A+state+attained+by+all+activated+human+T-cells&amp;rft.volume=123&amp;rft.pages=18-29&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1868523&amp;rft_id=info%3Adoi%2F10.1016%2Fj.clim.2006.10.014&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1868523&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ATheralizumab\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-14\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-14\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.jem.org/cgi/content/full/190/4/487\">\"Expression of CD28 and CD86 by Human Eosinophils and Role in the Secretion of Type 1 Cytokines (Interleukin 2 and Interferon {gamma}): Inhibition by Immunoglobulin A Complexes\"</a>, JEM, Volume 190, Number 4, 16 August 1999</span>\n</li>\n<li id=\"cite_note-15\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-15\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.jleukbio.org/cgi/content/abstract/72/4/769\">\"Human eosinophils express and release IL-13 following CD28-dependent activation\"</a>, Gaetane Woerly, Paige Lacy, Amena Ben Younes, Nadine Roger, Sylvie Loiseau, Redwan Moqbel and Monique Capron, Journal of Leukocyte Biology, 2002</span>\n</li>\n<li id=\"cite_note-16\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-16\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20070821215621/http://www.mhra.gov.uk/home/idcplg?IdcService=GET_FILE&amp;dDocName=CON2023519&amp;RevisionSelectionMethod=LatestReleased\">\"Investigations into adverse incidents during clinical trials of TGN1412\"</a>. MHRA. Archived from <a rel=\"nofollow\" class=\"external text\" href=\"http://www.mhra.gov.uk/home/idcplg?IdcService=GET_FILE&amp;dDocName=CON2023519&amp;RevisionSelectionMethod=LatestReleased\">the original</a> on 2007-08-21.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Investigations+into+adverse+incidents+during+clinical+trials+of+TGN1412&amp;rft.pub=MHRA&amp;rft_id=http%3A%2F%2Fwww.mhra.gov.uk%2Fhome%2Fidcplg%3FIdcService%3DGET_FILE%26dDocName%3DCON2023519%26RevisionSelectionMethod%3DLatestReleased&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ATheralizumab\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-17\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-17\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">DANIEL, MELK, S\u00dcSAL, WEIMER, ZIMMERMANN, HUTH-K\u00dcHNE, OPELZ (March 1999). <a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC1905242\">\"CD4 depletion in HIV-infected haemophilia patients is associated with rapid clearance of immune complex-coated CD4+ lymphocytes\"</a>. <i>Clinical &amp; Experimental Immunology</i>. <b>115</b> (3): 477\u2013484. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1046/j.1365-2249.1999.00848.x\">10.1046/j.1365-2249.1999.00848.x</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC1905242\">1905242</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Clinical+%26+Experimental+Immunology&amp;rft.atitle=CD4+depletion+in+HIV-infected+haemophilia+patients+is+associated+with+rapid+clearance+of+immune+complex-coated+CD4%2B+lymphocytes&amp;rft.volume=115&amp;rft.issue=3&amp;rft.pages=477-484&amp;rft.date=1999-03&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1905242&amp;rft_id=info%3Adoi%2F10.1046%2Fj.1365-2249.1999.00848.x&amp;rft.au=DANIEL%2C+MELK%2C+S%C3%9CSAL%2C+WEIMER%2C+ZIMMERMANN%2C+HUTH-K%C3%9CHNE%2C+OPELZ&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1905242&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ATheralizumab\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span><span class=\"citation-comment\" style=\"display:none; color:#33aa33; margin-left:0.3em\">CS1 maint: Multiple names: authors list (<a href=\"/wiki/Category:CS1_maint:_Multiple_names:_authors_list\" title=\"Category:CS1 maint: Multiple names: authors list\">link</a>) </span></span>\n</li>\n<li id=\"cite_note-Parexel2005-03-15-18\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-Parexel2005-03-15_18-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation pressrelease\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.parexel.com/news_and_events/press_releasesSingle.asp?id=233\">\"Media Advisory: PAREXEL International Statement Regarding TeGenero AG Phase I Trial at Northwick Park Hospital, UK\"</a> (Press release). PAREXEL. 2006-03-13.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Media+Advisory%3A+PAREXEL+International+Statement+Regarding+TeGenero+AG+Phase+I+Trial+at+Northwick+Park+Hospital%2C+UK&amp;rft.pub=PAREXEL&amp;rft.date=2006-03-13&amp;rft_id=http%3A%2F%2Fwww.parexel.com%2Fnews_and_events%2Fpress_releasesSingle.asp%3Fid%3D233&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ATheralizumab\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-njem-19\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-njem_19-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-njem_19-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-njem_19-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-njem_19-3\"><sup><i><b>d</b></i></sup></a></span> <span class=\"reference-text\">Suntharalingam G, Perry MR, Ward S, et al., <a rel=\"nofollow\" class=\"external text\" href=\"http://content.nejm.org/cgi/content/full/355/10/1018\">Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412</a>, <i><a href=\"/wiki/New_England_Journal_of_Medicine\" class=\"mw-redirect\" title=\"New England Journal of Medicine\">New England Journal of Medicine</a></i> 7 September 2006, vol.355, p.1018&#8211;1028.</span>\n</li>\n<li id=\"cite_note-BBC2006-03-18-20\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-BBC2006-03-18_20-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\"><a rel=\"nofollow\" class=\"external text\" href=\"http://news.bbc.co.uk/1/hi/england/london/4820188.stm\">\"Drugs trial men 'are improving<span style=\"padding-right:0.2em;\">'</span>\"</a>. <i>BBC News</i>. 2006-03-18<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2006-03-18</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=BBC+News&amp;rft.atitle=Drugs+trial+men+%27are+improving%27&amp;rft.date=2006-03-18&amp;rft_id=http%3A%2F%2Fnews.bbc.co.uk%2F1%2Fhi%2Fengland%2Flondon%2F4820188.stm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ATheralizumab\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-21\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-21\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external free\" href=\"https://www.telegraph.co.uk/finance/personalfinance/11089564/Would-you-accept-3750-to-trial-one-drug.html\">https://www.telegraph.co.uk/finance/personalfinance/11089564/Would-you-accept-3750-to-trial-one-drug.html</a></span>\n</li>\n<li id=\"cite_note-22\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-22\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.nwlh.nhs.uk/news/item.cfm?id=97\">Press releases by North West London Hospitals NHS Trust</a>, 5 July 2006</span>\n</li>\n<li id=\"cite_note-USpatent-23\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-USpatent_23-0\">^</a></b></span> <span class=\"reference-text\">United States patent application US20060009382 filed by Thomas Hanke, Chia-Huey Lin</span>\n</li>\n<li id=\"cite_note-ft2006-03-16-24\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-ft2006-03-16_24-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\">Lisa Urquhart; Andrew Jack (2006-03-16). <a rel=\"nofollow\" class=\"external text\" href=\"http://news.ft.com/cms/s/0a2ebf2a-b529-11da-aa90-0000779e2340.html\">\"Data for botched drugs trial show 'nothing' amiss\"</a>. <i>Financial Times</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2006-03-17</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Financial+Times&amp;rft.atitle=Data+for+botched+drugs+trial+show+%E2%80%98nothing%E2%80%99+amiss&amp;rft.date=2006-03-16&amp;rft.au=Lisa+Urquhart&amp;rft.au=Andrew+Jack&amp;rft_id=http%3A%2F%2Fnews.ft.com%2Fcms%2Fs%2F0a2ebf2a-b529-11da-aa90-0000779e2340.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ATheralizumab\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Reuters2006-03-19-25\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-Reuters2006-03-19_25-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\">Patricia Reaney (19 March 2006). <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20051231104428/http://today.reuters.co.uk/news/newsArticle.aspx?type=topNews\">\"Protein differences may explain drug reaction\"</a>. <i>Reuters</i>. Archived from <a rel=\"nofollow\" class=\"external text\" href=\"http://today.reuters.co.uk/news/newsArticle.aspx?type=topNews&amp;storyID=2006-03-19T143944Z_01_L19788458_RTRUKOC_0_UK-BRITAIN-TRIAL-EXPERT.xml&amp;archived=False\">the original</a> on 31 December 2005<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">19 March</span> 2006</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Reuters&amp;rft.atitle=Protein+differences+may+explain+drug+reaction&amp;rft.date=2006-03-19&amp;rft.au=Patricia+Reaney&amp;rft_id=http%3A%2F%2Ftoday.reuters.co.uk%2Fnews%2FnewsArticle.aspx%3Ftype%3DtopNews%26storyID%3D2006-03-19T143944Z_01_L19788458_RTRUKOC_0_UK-BRITAIN-TRIAL-EXPERT.xml%26archived%3DFalse&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ATheralizumab\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-26\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-26\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Waibler Z;  et al. (2008). \"Toward experimental assessment of receptor occupancy: TGN1412 revisited\". <i>Journal of Allergy and Clinical Immunology</i>. <b>122</b> (5): 890&#8211;892. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1016/j.jaci.2008.07.049\">10.1016/j.jaci.2008.07.049</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Allergy+and+Clinical+Immunology&amp;rft.atitle=Toward+experimental+assessment+of+receptor+occupancy%3A+TGN1412+revisited.&amp;rft.volume=122&amp;rft.issue=5&amp;rft.pages=890-892&amp;rft.date=2008&amp;rft_id=info%3Adoi%2F10.1016%2Fj.jaci.2008.07.049&amp;rft.au=Waibler+Z&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ATheralizumab\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-newscientist20060317-27\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-newscientist20060317_27-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\">Shaoni Bhattacharya; Andy Coghlan (2006-03-17). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.newscientist.com/article/dn8863-catastrophic-immune-response-may-have-caused-drug-trial-horror.html\">\"Catastrophic immune response may have caused drug trial horror\"</a>. <i>New Scientist</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2006-03-19</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=New+Scientist&amp;rft.atitle=Catastrophic+immune+response+may+have+caused+drug+trial+horror&amp;rft.date=2006-03-17&amp;rft.au=Shaoni+Bhattacharya&amp;rft.au=Andy+Coghlan&amp;rft_id=https%3A%2F%2Fwww.newscientist.com%2Farticle%2Fdn8863-catastrophic-immune-response-may-have-caused-drug-trial-horror.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ATheralizumab\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-telegraph20060317-28\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-telegraph20060317_28-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\">Celia Hall (2006-03-17). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.telegraph.co.uk/news/main.jhtml?xml=/news/2006/03/17/ntrial117.xml&amp;sSheet=/news/2006/03/17/ixhome.html\">\"Antibody 'puts immune system in overdrive<span style=\"padding-right:0.2em;\">'</span>\"</a>. <i>Telegraph</i>. London<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2006-03-19</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Telegraph&amp;rft.atitle=Antibody+%27puts+immune+system+in+overdrive%27&amp;rft.date=2006-03-17&amp;rft.au=Celia+Hall&amp;rft_id=https%3A%2F%2Fwww.telegraph.co.uk%2Fnews%2Fmain.jhtml%3Fxml%3D%2Fnews%2F2006%2F03%2F17%2Fntrial117.xml%26sSheet%3D%2Fnews%2F2006%2F03%2F17%2Fixhome.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ATheralizumab\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-bbc20060320-29\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-bbc20060320_29-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\"><a rel=\"nofollow\" class=\"external text\" href=\"http://news.bbc.co.uk/1/hi/england/london/4823992.stm\">\"Trial drug affected animal glands\"</a>. <i>BBC News</i>. 2006-03-20<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2006-03-20</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=BBC+News&amp;rft.atitle=Trial+drug+affected+animal+glands&amp;rft.date=2006-03-20&amp;rft_id=http%3A%2F%2Fnews.bbc.co.uk%2F1%2Fhi%2Fengland%2Flondon%2F4823992.stm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ATheralizumab\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-tegenero20060319-30\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-tegenero20060319_30-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20060521150601/http://www.tegenero.com/news/faqs_re_tgn1412/index.php\">\"Update to frequently asked questions regarding TGN1412\"</a>. <i>TeGenero</i>. 2006-03-19. Archived from <a rel=\"nofollow\" class=\"external text\" href=\"http://www.tegenero.com/news/faqs_re_tgn1412/index.php\">the original</a> on 21 May 2006<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2006-03-20</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=TeGenero&amp;rft.atitle=Update+to+frequently+asked+questions+regarding+TGN1412&amp;rft.date=2006-03-19&amp;rft_id=http%3A%2F%2Fwww.tegenero.com%2Fnews%2Ffaqs_re_tgn1412%2Findex.php&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ATheralizumab\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-nature20060317-31\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-nature20060317_31-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\">Helen Pearson (2006-03-17). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.nature.com/news/2006/060313/full/060313-17.html\">\"Tragic drug trial spotlights potent molecule\"</a>. <i>Nature</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2006-03-19</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Nature&amp;rft.atitle=Tragic+drug+trial+spotlights+potent+molecule&amp;rft.date=2006-03-17&amp;rft.au=Helen+Pearson&amp;rft_id=http%3A%2F%2Fwww.nature.com%2Fnews%2F2006%2F060313%2Ffull%2F060313-17.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ATheralizumab\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-rss2007-32\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-rss2007_32-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Working Party on Statistical Issues in First-in-Man Studies (2007). <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20120105003015/http://www.rss.org.uk/site/cms/contentviewarticle.asp?article=523\">\"Statistical issues in first-in-man studies\"</a>. <i>Journal of the Royal Statistical Society</i>. <b>170A</b>: 517&#8211;579. Archived from <a rel=\"nofollow\" class=\"external text\" href=\"http://www.rss.org.uk/site/cms/contentviewarticle.asp?article=523\">the original</a> on 5 January 2012.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+the+Royal+Statistical+Society&amp;rft.atitle=Statistical+issues+in+first-in-man+studies&amp;rft.volume=170A&amp;rft.pages=517-579&amp;rft.date=2007&amp;rft.au=Working+Party+on+Statistical+Issues+in+First-in-Man+Studies&amp;rft_id=http%3A%2F%2Fwww.rss.org.uk%2Fsite%2Fcms%2Fcontentviewarticle.asp%3Farticle%3D523&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ATheralizumab\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Akhtar_2014-33\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-Akhtar_2014_33-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Akhtar, Aysha (7 December 2014). <a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC4594046\">\"The Flaws and Human Harms of Animal Experimentation\"</a>. <i>Cambridge Quarterly of Healthcare Ethics</i>. <b>24</b> (4). <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1017/S0963180115000079\">10.1017/S0963180115000079</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC4594046\">4594046</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/26364776\">26364776</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Cambridge+Quarterly+of+Healthcare+Ethics&amp;rft.atitle=The+Flaws+and+Human+Harms+of+Animal+Experimentation&amp;rft.volume=24&amp;rft.issue=4&amp;rft.date=2014-12-07&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4594046&amp;rft_id=info%3Apmid%2F26364776&amp;rft_id=info%3Adoi%2F10.1017%2FS0963180115000079&amp;rft.aulast=Akhtar&amp;rft.aufirst=Aysha&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4594046&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ATheralizumab\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-MHRA20060405-34\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-MHRA20060405_34-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\">MHRA (2006-04-05). <a rel=\"nofollow\" class=\"external text\" href=\"http://webarchive.nationalarchives.gov.uk/20141205150130/http://www.mhra.gov.uk/NewsCentre/Pressreleases/CON2023515\">\"Press release: Latest findings on clinical trial suspension\"</a>. <i>Press Release</i>. Archived from <a rel=\"nofollow\" class=\"external text\" href=\"http://www.mhra.gov.uk/NewsCentre/Pressreleases/CON2023515\">the original</a> on 2014-12-05<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2010-06-04</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Press+Release&amp;rft.atitle=Press+release%3A+Latest+findings+on+clinical+trial+suspension&amp;rft.date=2006-04-05&amp;rft.au=MHRA&amp;rft_id=http%3A%2F%2Fwww.mhra.gov.uk%2FNewsCentre%2FPressreleases%2FCON2023515&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ATheralizumab\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-35\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-35\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Medicines and Healthcare Products Regulatory Agency (MHRA) (25 May 2006). <a rel=\"nofollow\" class=\"external text\" href=\"http://webarchive.nationalarchives.gov.uk/20141206051830/http://www.mhra.gov.uk/NewsCentre/Pressreleases/CON2023822\">\"Clinical trial final report\"</a>. <i>webarchive.nationalarchives.gov.uk</i>. Archived from the original on 6 December 2014<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">29 November</span> 2017</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=webarchive.nationalarchives.gov.uk&amp;rft.atitle=Clinical+trial+final+report&amp;rft.date=2006-05-25&amp;rft.au=Medicines+and+Healthcare+Products+Regulatory+Agency+%28MHRA%29&amp;rft_id=http%3A%2F%2Fwww.mhra.gov.uk%2FNewsCentre%2FPressreleases%2FCON2023822&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ATheralizumab\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span><span class=\"citation-comment\" style=\"display:none; color:#33aa33; margin-left:0.3em\">CS1 maint: BOT: original-url status unknown (<a href=\"/wiki/Category:CS1_maint:_BOT:_original-url_status_unknown\" title=\"Category:CS1 maint: BOT: original-url status unknown\">link</a>) </span></span>\n</li>\n<li id=\"cite_note-36\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-36\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://webarchive.nationalarchives.gov.uk/20110505014645/http://www.mhra.gov.uk/home/idcplg?IdcService=GET_FILE&amp;dDocName=CON2023519&amp;RevisionSelectionMethod=LatestReleased\">INVESTIGATIONS INTO ADVERSE INCIDENTS DURING CLINICAL TRIALS OF TGN1412</a> Medicines and Healthcare products Regulatory Agency (MHRA), 6pp, 5 April 2006.</span>\n</li>\n<li id=\"cite_note-37\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-37\">^</a></b></span> <span class=\"reference-text\">Expert Group on Phase One Clinical Trials: <a rel=\"nofollow\" class=\"external text\" href=\"http://webarchive.nationalarchives.gov.uk/20130107105354/http://dh.gov.uk/en/publicationsandstatistics/publications/publicationspolicyandguidance/dh_063117\">Final report</a> TSO (The Stationery Office)7 December 2006.</span>\n</li>\n<li id=\"cite_note-38\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-38\">^</a></b></span> <span class=\"reference-text\">Michael Day <a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1702450/\">Duff's report calls for changes in way drugs are tested</a> BMJ. 2006 Dec 16; 333(7581): 1240. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1136%2Fbmj.39062.336157.DB\">10.1136/bmj.39062.336157.DB</a></span>\n</li>\n<li id=\"cite_note-39\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-39\">^</a></b></span> <span class=\"reference-text\">Liedert B, Bassus S, Schneider CK, Kalinke U, L\u00f6wer J. <a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17256444\">Safety of phase I clinical trials with monoclonal antibodies in Germany--the regulatory requirements viewed in the aftermath of the TGN1412 disaster.</a> Int J Clin Pharmacol Ther. 2007 Jan;45(1):1-9.<span style=\"font-size:0.95em; font-size:90%; color:#555\">(subscription required)</span></span>\n</li>\n<li id=\"cite_note-40\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-40\">^</a></b></span> <span class=\"reference-text\">Stebbings R, Poole S, Thorpe R.  Safety of biologics, lessons learnt from TGN1412. Curr Opin Biotechnol. 2009 Dec;20(6):673-7. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1016%2Fj.copbio.2009.10.002\">10.1016/j.copbio.2009.10.002</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/19892543\">19892543</a><span style=\"font-size:0.95em; font-size:90%; color:#555\">(subscription required)</span></span>\n</li>\n<li id=\"cite_note-41\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-41\">^</a></b></span> <span class=\"reference-text\">Eastwood D1, Findlay L, Poole S, Bird C, Wadhwa M, Moore M, Burns C, Thorpe R, Stebbings R.  Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. Br J Pharmacol. 2010 Oct;161(3):512-26. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1111%2Fj.1476-5381.2010.00922.x\">10.1111/j.1476-5381.2010.00922.x</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/20880392\">20880392</a> <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a> <a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2990151/\">2990151</a></span>\n</li>\n<li id=\"cite_note-42\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-42\">^</a></b></span> <span class=\"reference-text\">Stebbings R, Eastwood D, Poole S, Thorpe R. <a rel=\"nofollow\" class=\"external text\" href=\"http://www.tandfonline.com/doi/full/10.3109/1547691X.2012.711783After\">TGN1412: recent developments in cytokine release assays</a>. Immunotoxicol. 2013 Jan-Mar;10(1):75-82. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.3109%2F1547691X.2012.711783\">10.3109/1547691X.2012.711783</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/22967038\">22967038</a></span>\n</li>\n</ol></div>\n<h2><span class=\"mw-headline\" id=\"External_links\">External links</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Theralizumab&amp;action=edit&amp;section=9\" title=\"Edit section: External links\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<ul><li><a rel=\"nofollow\" class=\"external text\" href=\"https://dx.doi.org/10.1038/440855a\">Report in Nature on TGN1412</a></li>\n<li><a rel=\"nofollow\" class=\"external text\" href=\"http://news.bbc.co.uk/1/hi/health/4914546.stm\">BBC News: Drug trial man 'may lose fingers'</a></li>\n<li><a rel=\"nofollow\" class=\"external text\" href=\"http://news.bbc.co.uk/1/hi/health/5015224.stm\">BBC News: Regulators slam drug trial firm</a></li>\n<li><a rel=\"nofollow\" class=\"external text\" href=\"http://briandeer.com/tgn1412/dispatches.htm\">Channel 4: The Drug Trial That Went Wrong</a></li>\n<li><a rel=\"nofollow\" class=\"external text\" href=\"http://www.nature.com/news/2007/070122/full/070122-10.html\">Nature news: Animal tests may have missed danger because monkeys 'too clean'</a></li>\n<li><a rel=\"nofollow\" class=\"external text\" href=\"http://rosettapr.com/perspectives.php\">crisis communications case study of Tegenero clinical trial</a></li>\n<li><a rel=\"nofollow\" class=\"external text\" href=\"http://bmj.bmjjournals.com/cgi/content/full/333/7562/270\">Further lessons from the TGN1412 tragedy</a></li></ul>\n<div role=\"navigation\" class=\"navbox\" aria-labelledby=\"Monoclonal_antibodies_for_the_immune_system\" style=\"padding:3px\"><table class=\"nowraplinks collapsible autocollapse navbox-inner\" style=\"border-spacing:0;background:transparent;color:inherit\"><tbody><tr><th scope=\"col\" class=\"navbox-title\" colspan=\"2\" style=\"text-align:center;\"><div class=\"plainlinks hlist navbar mini\"><ul><li class=\"nv-view\"><a href=\"/wiki/Template:Monoclonals_for_immune_system\" title=\"Template:Monoclonals for immune system\"><abbr title=\"View this template\" style=\"text-align:center;;;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none; padding:0;\">v</abbr></a></li><li class=\"nv-talk\"><a href=\"/wiki/Template_talk:Monoclonals_for_immune_system\" title=\"Template talk:Monoclonals for immune system\"><abbr title=\"Discuss this template\" style=\"text-align:center;;;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none; padding:0;\">t</abbr></a></li><li class=\"nv-edit\"><a class=\"external text\" href=\"//en.wikipedia.org/w/index.php?title=Template:Monoclonals_for_immune_system&amp;action=edit\"><abbr title=\"Edit this template\" style=\"text-align:center;;;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none; padding:0;\">e</abbr></a></li></ul></div><div id=\"Monoclonal_antibodies_for_the_immune_system\" style=\"font-size:114%;margin:0 4em\"><a href=\"/wiki/Monoclonal_antibodies\" class=\"mw-redirect\" title=\"Monoclonal antibodies\">Monoclonal antibodies</a> for the <a href=\"/wiki/Immune_system\" title=\"Immune system\">immune system</a></div></th></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"text-align:center;;width:1%\"><a href=\"/wiki/Immune_system\" title=\"Immune system\">Immune system</a> (\"-l(i[m])-\")</th><td class=\"navbox-list navbox-odd hlist\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\"></div><table class=\"nowraplinks navbox-subgroup\" style=\"border-spacing:0\"><tbody><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%;text-align:center;\">Human (\"-limu-\")</th><td class=\"navbox-list navbox-odd\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><i><a href=\"/wiki/Immunosuppression\" title=\"Immunosuppression\">Immunosuppression</a></i>: <a href=\"/wiki/Abrilumab\" title=\"Abrilumab\">Abrilumab</a></li>\n<li><a href=\"/wiki/Adalimumab\" title=\"Adalimumab\">Adalimumab</a></li>\n<li><a href=\"/wiki/Anifrolumab\" title=\"Anifrolumab\">Anifrolumab</a><sup>\u2020</sup></li>\n<li><a href=\"/wiki/Atorolimumab\" title=\"Atorolimumab\">Atorolimumab</a></li>\n<li><a href=\"/wiki/Avelumab\" title=\"Avelumab\">Avelumab</a></li>\n<li><a href=\"/wiki/Belimumab\" title=\"Belimumab\">Belimumab</a></li>\n<li><a href=\"/wiki/Bleselumab\" title=\"Bleselumab\">Bleselumab</a></li>\n<li><a href=\"/wiki/Brodalumab\" title=\"Brodalumab\">Brodalumab</a></li>\n<li><a href=\"/wiki/Camidanlumab_tesirine\" title=\"Camidanlumab tesirine\">Camidanlumab tesirine</a></li>\n<li><a href=\"/wiki/Carlumab\" title=\"Carlumab\">Carlumab</a></li>\n<li><a href=\"/wiki/Cemiplimab\" title=\"Cemiplimab\">Cemiplimab</a></li>\n<li><a href=\"/wiki/Dupilumab\" title=\"Dupilumab\">Dupilumab</a></li>\n<li><a href=\"/wiki/Eldelumab\" title=\"Eldelumab\">Eldelumab</a></li>\n<li><a href=\"/wiki/Emapalumab\" title=\"Emapalumab\">Emapalumab</a><sup>\u2020</sup></li>\n<li><a href=\"/wiki/Fresolimumab\" title=\"Fresolimumab\">Fresolimumab</a></li>\n<li><a href=\"/wiki/Gimsilumab\" title=\"Gimsilumab\">Gimsilumab</a></li>\n<li><a href=\"/wiki/Golimumab\" title=\"Golimumab\">Golimumab</a></li>\n<li><a href=\"/wiki/Lanadelumab\" title=\"Lanadelumab\">Lanadelumab</a></li>\n<li><a href=\"/wiki/Lenzilumab\" title=\"Lenzilumab\">Lenzilumab</a></li>\n<li><a href=\"/wiki/Lerdelimumab\" title=\"Lerdelimumab\">Lerdelimumab</a></li>\n<li><a href=\"/wiki/Lirilumab\" title=\"Lirilumab\">Lirilumab</a></li>\n<li><a href=\"/wiki/Mavrilimumab\" title=\"Mavrilimumab\">Mavrilimumab</a></li>\n<li><a href=\"/wiki/Metelimumab\" title=\"Metelimumab\">Metelimumab</a></li>\n<li><a href=\"/wiki/Morolimumab\" title=\"Morolimumab\">Morolimumab</a></li>\n<li><a href=\"/wiki/Namilumab\" title=\"Namilumab\">Namilumab</a></li>\n<li><a href=\"/wiki/Oleclumab\" title=\"Oleclumab\">Oleclumab</a></li>\n<li><a href=\"/wiki/Oxelumab\" title=\"Oxelumab\">Oxelumab</a>\u00a7</li>\n<li><a href=\"/wiki/Pamrevlumab\" title=\"Pamrevlumab\">Pamrevlumab</a></li>\n<li><a href=\"/wiki/Placulumab\" title=\"Placulumab\">Placulumab</a></li>\n<li><a href=\"/wiki/Sarilumab\" title=\"Sarilumab\">Sarilumab</a></li>\n<li><a href=\"/wiki/Sifalimumab\" title=\"Sifalimumab\">Sifalimumab</a></li>\n<li><a href=\"/wiki/Tabalumab\" title=\"Tabalumab\">Tabalumab</a></li>\n<li><a href=\"/wiki/Tezepelumab\" title=\"Tezepelumab\">Tezepelumab</a><sup>\u2020</sup></li>\n<li><a href=\"/wiki/Ulocuplumab\" title=\"Ulocuplumab\">Ulocuplumab</a></li>\n<li><a href=\"/wiki/Varlilumab\" title=\"Varlilumab\">Varlilumab</a></li></ul>\n<ul><li><i>Immune activation</i>: <a href=\"/wiki/Ipilimumab\" title=\"Ipilimumab\">Ipilimumab</a></li>\n<li><a href=\"/wiki/Atezolizumab\" title=\"Atezolizumab\">Atezolizumab</a></li>\n<li><a href=\"/wiki/Durvalumab\" title=\"Durvalumab\">Durvalumab</a></li>\n<li><a href=\"/wiki/Nivolumab\" title=\"Nivolumab\">Nivolumab</a></li>\n<li><a href=\"/wiki/Pembrolizumab\" title=\"Pembrolizumab\">Pembrolizumab</a></li>\n<li><a href=\"/wiki/Tremelimumab\" title=\"Tremelimumab\">Tremelimumab</a><sup>\u2020</sup></li>\n<li><a href=\"/wiki/Urelumab\" title=\"Urelumab\">Urelumab</a></li></ul>\n<ul><li><i>Other</i>: <a href=\"/wiki/Bertilimumab\" title=\"Bertilimumab\">Bertilimumab</a></li>\n<li><a href=\"/wiki/Zanolimumab\" title=\"Zanolimumab\">Zanolimumab</a></li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%;text-align:center;\">Mouse (\"-limo-\")</th><td class=\"navbox-list navbox-even\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/Afelimomab\" title=\"Afelimomab\">Afelimomab</a></li>\n<li><a href=\"/wiki/Elsilimomab\" title=\"Elsilimomab\">Elsilimomab</a></li>\n<li><a href=\"/wiki/Faralimomab\" title=\"Faralimomab\">Faralimomab</a></li>\n<li><a href=\"/wiki/Gavilimomab\" title=\"Gavilimomab\">Gavilimomab</a></li>\n<li><a href=\"/wiki/Inolimomab\" title=\"Inolimomab\">Inolimomab</a></li>\n<li><a href=\"/wiki/Maslimomab\" title=\"Maslimomab\">Maslimomab</a></li>\n<li><a href=\"/wiki/Nerelimomab\" title=\"Nerelimomab\">Nerelimomab</a></li>\n<li><a href=\"/wiki/Odulimomab\" title=\"Odulimomab\">Odulimomab</a></li>\n<li><a href=\"/wiki/Telimomab_aritox\" title=\"Telimomab aritox\">Telimomab aritox</a></li>\n<li><a href=\"/wiki/Vepalimomab\" title=\"Vepalimomab\">Vepalimomab</a></li>\n<li><a href=\"/wiki/Zolimomab_aritox\" title=\"Zolimomab aritox\">Zolimomab aritox</a></li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%;text-align:center;\"><a href=\"/wiki/Chimeric_antibody\" class=\"mw-redirect\" title=\"Chimeric antibody\">Chimeric</a> (\"-lixi-\")</th><td class=\"navbox-list navbox-odd\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/Andecaliximab\" title=\"Andecaliximab\">Andecaliximab</a><sup>\u2020</sup></li>\n<li><a href=\"/wiki/Basiliximab\" title=\"Basiliximab\">Basiliximab</a></li>\n<li><a href=\"/wiki/Clenoliximab\" title=\"Clenoliximab\">Clenoliximab</a></li>\n<li><a href=\"/wiki/Galiximab\" title=\"Galiximab\">Galiximab</a></li>\n<li><a href=\"/wiki/Gomiliximab\" class=\"mw-redirect\" title=\"Gomiliximab\">Gomiliximab</a></li>\n<li><a href=\"/wiki/Infliximab\" title=\"Infliximab\">Infliximab</a></li>\n<li><a href=\"/wiki/Keliximab\" title=\"Keliximab\">Keliximab</a></li>\n<li><a href=\"/wiki/Lumiliximab\" title=\"Lumiliximab\">Lumiliximab</a></li>\n<li><a href=\"/wiki/Priliximab\" title=\"Priliximab\">Priliximab</a></li>\n<li><a href=\"/wiki/Teneliximab\" title=\"Teneliximab\">Teneliximab</a></li>\n<li><a href=\"/wiki/Vapaliximab\" title=\"Vapaliximab\">Vapaliximab</a></li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%;text-align:center;\"><a href=\"/wiki/Humanized_antibody\" title=\"Humanized antibody\">Humanized</a> (\"-lizu-\")</th><td class=\"navbox-list navbox-even\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><i>Immunosuppressive:</i> <a href=\"/wiki/Aselizumab\" title=\"Aselizumab\">Aselizumab</a></li>\n<li><a href=\"/wiki/Apolizumab\" title=\"Apolizumab\">Apolizumab</a><sup>\u00a7</sup></li>\n<li><a href=\"/wiki/Benralizumab\" title=\"Benralizumab\">Benralizumab</a></li>\n<li><a href=\"/wiki/Cedelizumab\" title=\"Cedelizumab\">Cedelizumab</a></li>\n<li><a href=\"/wiki/Certolizumab_pegol\" title=\"Certolizumab pegol\">Certolizumab pegol</a></li>\n<li><a href=\"/wiki/Crizanlizumab\" title=\"Crizanlizumab\">Crizanlizumab</a><sup>\u2020</sup></li>\n<li><a href=\"/wiki/Daclizumab\" title=\"Daclizumab\">Daclizumab</a></li>\n<li><a href=\"/wiki/Eculizumab\" title=\"Eculizumab\">Eculizumab</a></li>\n<li><a href=\"/wiki/Efalizumab\" title=\"Efalizumab\">Efalizumab</a></li>\n<li><a href=\"/wiki/Epratuzumab\" title=\"Epratuzumab\">Epratuzumab</a></li>\n<li><a href=\"/wiki/Erlizumab\" title=\"Erlizumab\">Erlizumab</a></li>\n<li><a href=\"/wiki/Etrolizumab\" title=\"Etrolizumab\">Etrolizumab</a><sup>\u2020</sup></li>\n<li><a href=\"/wiki/Fontolizumab\" title=\"Fontolizumab\">Fontolizumab</a></li>\n<li><a href=\"/wiki/Inebilizumab\" title=\"Inebilizumab\">Inebilizumab</a><sup>\u2020</sup></li>\n<li><a href=\"/wiki/Itolizumab\" title=\"Itolizumab\">Itolizumab</a></li>\n<li><a href=\"/wiki/Lampalizumab\" title=\"Lampalizumab\">Lampalizumab</a><sup>\u2020</sup></li>\n<li><a href=\"/wiki/Letolizumab\" title=\"Letolizumab\">Letolizumab</a></li>\n<li><a href=\"/wiki/Ligelizumab\" title=\"Ligelizumab\">Ligelizumab</a></li>\n<li><a href=\"/wiki/Lulizumab_pegol\" title=\"Lulizumab pegol\">Lulizumab pegol</a></li>\n<li><a href=\"/wiki/Mepolizumab\" title=\"Mepolizumab\">Mepolizumab</a></li>\n<li><a href=\"/wiki/Mogamulizumab\" title=\"Mogamulizumab\">Mogamulizumab</a></li>\n<li><a href=\"/wiki/Natalizumab\" title=\"Natalizumab\">Natalizumab</a></li>\n<li><a href=\"/wiki/Ocrelizumab\" title=\"Ocrelizumab\">Ocrelizumab</a></li>\n<li><a href=\"/wiki/Omalizumab\" title=\"Omalizumab\">Omalizumab</a></li>\n<li><a href=\"/wiki/Ozoralizumab\" title=\"Ozoralizumab\">Ozoralizumab</a></li>\n<li><a href=\"/wiki/Pascolizumab\" title=\"Pascolizumab\">Pascolizumab</a></li>\n<li><a href=\"/wiki/Pateclizumab\" title=\"Pateclizumab\">Pateclizumab</a></li>\n<li><a href=\"/wiki/Pembrolizumab\" title=\"Pembrolizumab\">Pembrolizumab</a></li>\n<li><a href=\"/wiki/Pexelizumab\" title=\"Pexelizumab\">Pexelizumab</a></li>\n<li><a href=\"/wiki/Pidilizumab\" title=\"Pidilizumab\">Pidilizumab</a></li>\n<li><a href=\"/wiki/Plozalizumab\" title=\"Plozalizumab\">Plozalizumab</a></li>\n<li><a href=\"/wiki/PRO_140\" title=\"PRO 140\">PRO 140</a><sup>\u2020</sup></li>\n<li><a href=\"/wiki/Quilizumab\" title=\"Quilizumab\">Quilizumab</a></li>\n<li><a href=\"/wiki/Ravulizumab\" title=\"Ravulizumab\">Ravulizumab</a><sup>\u2020</sup></li>\n<li><a href=\"/wiki/Reslizumab\" title=\"Reslizumab\">Reslizumab</a></li>\n<li><a href=\"/wiki/Rontalizumab\" title=\"Rontalizumab\">Rontalizumab</a></li>\n<li><a href=\"/wiki/Rovelizumab\" title=\"Rovelizumab\">Rovelizumab</a></li>\n<li><a href=\"/wiki/Ruplizumab\" title=\"Ruplizumab\">Ruplizumab</a></li>\n<li><a href=\"/wiki/Samalizumab\" title=\"Samalizumab\">Samalizumab</a></li>\n<li><a href=\"/wiki/Siplizumab\" title=\"Siplizumab\">Siplizumab</a></li>\n<li><a href=\"/wiki/Talizumab\" title=\"Talizumab\">Talizumab</a></li>\n<li><a href=\"/wiki/Teplizumab\" title=\"Teplizumab\">Teplizumab</a></li>\n<li><a href=\"/wiki/Tibulizumab\" title=\"Tibulizumab\">Tibulizumab</a></li>\n<li><a href=\"/wiki/Tislelizumab\" title=\"Tislelizumab\">Tislelizumab</a></li>\n<li><a href=\"/wiki/Tocilizumab\" title=\"Tocilizumab\">Tocilizumab</a></li>\n<li><a href=\"/wiki/Toralizumab\" title=\"Toralizumab\">Toralizumab</a></li>\n<li><a href=\"/wiki/Tregalizumab\" title=\"Tregalizumab\">Tregalizumab</a></li>\n<li><a href=\"/wiki/Vatelizumab\" title=\"Vatelizumab\">Vatelizumab</a></li>\n<li><a href=\"/wiki/Vedolizumab\" title=\"Vedolizumab\">Vedolizumab</a></li>\n<li><a href=\"/wiki/Visilizumab\" title=\"Visilizumab\">Visilizumab</a></li>\n<li><a href=\"/wiki/Vobarilizumab\" title=\"Vobarilizumab\">Vobarilizumab</a></li>\n<li><a href=\"/wiki/TGN1412\" class=\"mw-redirect\" title=\"TGN1412\">TGN1412</a><sup>\u00a7</sup><br /><i>Non-immunosuppressive:</i> <a href=\"/wiki/Ibalizumab\" title=\"Ibalizumab\">Ibalizumab</a></li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%;text-align:center;\">Chimeric + humanized<br />(\"-lixizu-\")</th><td class=\"navbox-list navbox-odd\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/Otelixizumab\" title=\"Otelixizumab\">Otelixizumab</a></li>\n<li><a href=\"/wiki/Tavolimab\" title=\"Tavolimab\">Tavolimab</a></li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%;text-align:center;\"><a href=\"/wiki/Veterinary_medicine\" title=\"Veterinary medicine\">Veterinary</a> (\"-lvet-\")</th><td class=\"navbox-list navbox-even\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\"><a href=\"/wiki/Gilvetmab\" title=\"Gilvetmab\">Gilvetmab</a></div></td></tr></tbody></table><div></div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"text-align:center;;width:1%\"><a href=\"/wiki/Interleukin\" title=\"Interleukin\">Interleukin</a> (\"-k(i[n])-\")</th><td class=\"navbox-list navbox-odd hlist\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\"></div><table class=\"nowraplinks navbox-subgroup\" style=\"border-spacing:0\"><tbody><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%;text-align:center;\">Human (\"-kinu-\")</th><td class=\"navbox-list navbox-odd\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/Brazikumab\" title=\"Brazikumab\">Brazikumab</a></li>\n<li><a href=\"/wiki/Briakinumab\" title=\"Briakinumab\">Briakinumab</a></li>\n<li><a href=\"/wiki/Canakinumab\" title=\"Canakinumab\">Canakinumab</a></li>\n<li><a href=\"/wiki/Fezakinumab\" title=\"Fezakinumab\">Fezakinumab</a></li>\n<li><a href=\"/wiki/Fletikumab\" title=\"Fletikumab\">Fletikumab</a></li>\n<li><a href=\"/wiki/Guselkumab\" title=\"Guselkumab\">Guselkumab</a></li>\n<li><a href=\"/wiki/Secukinumab\" title=\"Secukinumab\">Secukinumab</a></li>\n<li><a href=\"/wiki/Sirukumab\" title=\"Sirukumab\">Sirukumab</a></li>\n<li><a href=\"/wiki/Tralokinumab\" title=\"Tralokinumab\">Tralokinumab</a><sup>\u2020</sup></li>\n<li><a href=\"/wiki/Ustekinumab\" title=\"Ustekinumab\">Ustekinumab</a></li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%;text-align:center;\">Humanized (\"-kizu-\", \"-kinzu-\")</th><td class=\"navbox-list navbox-even\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/Anrukinzumab\" title=\"Anrukinzumab\">Anrukinzumab</a></li>\n<li><a href=\"/wiki/Clazakizumab\" title=\"Clazakizumab\">Clazakizumab</a></li>\n<li><a href=\"/wiki/Enokizumab\" title=\"Enokizumab\">Enokizumab</a></li>\n<li><a href=\"/wiki/Gevokizumab\" title=\"Gevokizumab\">Gevokizumab</a></li>\n<li><a href=\"/wiki/Ixekizumab\" title=\"Ixekizumab\">Ixekizumab</a></li>\n<li><a href=\"/wiki/Mirikizumab\" title=\"Mirikizumab\">Mirikizumab</a></li>\n<li><a href=\"/wiki/Lebrikizumab\" title=\"Lebrikizumab\">Lebrikizumab</a></li>\n<li><a href=\"/wiki/Olokizumab\" title=\"Olokizumab\">Olokizumab</a><sup>\u2020</sup></li>\n<li><a href=\"/wiki/Perakizumab\" title=\"Perakizumab\">Perakizumab</a></li>\n<li><a href=\"/wiki/Risankizumab\" title=\"Risankizumab\">Risankizumab</a><sup>\u2020</sup></li>\n<li><a href=\"/wiki/Tildrakizumab\" title=\"Tildrakizumab\">Tildrakizumab</a></li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%;text-align:center;\">Veterinary (\"-kivet-\")</th><td class=\"navbox-list navbox-odd\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/Lokivetmab\" title=\"Lokivetmab\">Lokivetmab</a></li></ul>\n</div></td></tr></tbody></table><div></div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"text-align:center;;width:1%\">Inflammatory <a href=\"/wiki/Lesion\" title=\"Lesion\">lesions</a> (\"-les-\")</th><td class=\"navbox-list navbox-odd hlist\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\"></div><table class=\"nowraplinks navbox-subgroup\" style=\"border-spacing:0\"><tbody><tr><th id=\"Mouse_(&amp;quot;-leso-&amp;quot;)\" scope=\"row\" class=\"navbox-group\" style=\"width:1%;text-align:center;\">Mouse (\"-leso-\")</th><td class=\"navbox-list navbox-even\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/Besilesomab\" title=\"Besilesomab\">Besilesomab</a></li>\n<li><a href=\"/wiki/Technetium_(99mTc)_fanolesomab\" title=\"Technetium (99mTc) fanolesomab\">Fanolesomab</a><sup>\u2021</sup></li>\n<li><a href=\"/wiki/Lemalesomab\" title=\"Lemalesomab\">Lemalesomab</a></li>\n<li><a href=\"/wiki/Technetium_(99mTc)_sulesomab\" title=\"Technetium (99mTc) sulesomab\">Sulesomab</a></li></ul>\n</div></td></tr></tbody></table><div></div></td></tr><tr><td class=\"navbox-abovebelow\" colspan=\"2\" style=\"text-align:center;;background: transparent; padding: 0px;\"><div><div class=\"hlist\">\n<ul><li><sup>#</sup><a href=\"/wiki/WHO_Model_List_of_Essential_Medicines\" title=\"WHO Model List of Essential Medicines\">WHO-EM</a></li>\n<li><sup>\u2021</sup><a href=\"/wiki/List_of_withdrawn_drugs\" title=\"List of withdrawn drugs\">Withdrawn</a> from market</li>\n<li><a href=\"/wiki/Clinical_trial\" title=\"Clinical trial\">Clinical trials</a>:\n<ul><li><sup>\u2020</sup><a href=\"/wiki/Phases_of_clinical_research#Phase_III\" title=\"Phases of clinical research\">Phase III</a></li>\n<li><sup>\u00a7</sup>Never to phase III</li></ul></li></ul>\n</div></div></td></tr></tbody></table></div>\n<p class=\"mw-empty-elt\">\n</p>\n<!-- \nNewPP limit report\nParsed by mw2233\nCached time: 20180918021339\nCache expiry: 1900800\nDynamic content: false\nCPU time usage: 0.692 seconds\nReal time usage: 1.134 seconds\nPreprocessor visited node count: 5636/1000000\nPreprocessor generated node count: 0/1500000\nPost\u2010expand include size: 111172/2097152 bytes\nTemplate argument size: 4362/2097152 bytes\nHighest expansion depth: 16/40\nExpensive parser function count: 5/500\nUnstrip recursion depth: 0/20\nUnstrip post\u2010expand size: 45784/5000000 bytes\nNumber of Wikibase entities loaded: 1/400\nLua time usage: 0.266/10.000 seconds\nLua memory usage: 5.18 MB/50 MB\n-->\n<!--\nTransclusion expansion time report (%,ms,calls,template)\n100.00%  873.024      1 -total\n 47.72%  416.589      1 Template:Reflist\n 38.77%  338.513      1 Template:Drugbox\n 27.21%  237.559      4 Template:Cite_web\n 24.15%  210.793      1 Template:Infobox\n  7.02%   61.294     16 Template:Unbulleted_list\n  6.24%   54.444      3 Template:Citation_needed\n  5.42%   47.347      3 Template:Fix\n  5.23%   45.669      8 Template:Cite_journal\n  4.87%   42.476     10 Template:Cite_news\n-->\n\n<!-- Saved in parser cache with key enwiki:pcache:idhash:4402358-0!canonical and timestamp 20180918021338 and revision id 860060983\n -->\n</div>"},"langlinks":[{"lang":"de","url":"https://de.wikipedia.org/wiki/TGN1412","langname":"German","autonym":"Deutsch","*":"TGN1412"},{"lang":"eo","url":"https://eo.wikipedia.org/wiki/TGN1412","langname":"Esperanto","autonym":"Esperanto","*":"TGN1412"},{"lang":"nl","url":"https://nl.wikipedia.org/wiki/TGN1412","langname":"Dutch","autonym":"Nederlands","*":"TGN1412"},{"lang":"pl","url":"https://pl.wikipedia.org/wiki/TGN1412","langname":"Polish","autonym":"polski","*":"TGN1412"},{"lang":"fi","url":"https://fi.wikipedia.org/wiki/TGN1412","langname":"Finnish","autonym":"suomi","*":"TGN1412"},{"lang":"sv","url":"https://sv.wikipedia.org/wiki/TGN1412","langname":"Swedish","autonym":"svenska","*":"TGN1412"}],"categories":[{"sortkey":"","hidden":"","*":"CS1_maint:_Multiple_names:_authors_list"},{"sortkey":"","hidden":"","*":"CS1_maint:_BOT:_original-url_status_unknown"},{"sortkey":"","hidden":"","*":"Pages_containing_links_to_subscription-only_content"},{"sortkey":"Tgn1412","*":"Drugs_not_assigned_an_ATC_code"},{"sortkey":" ","hidden":"","*":"Drugs_with_non-standard_legal_status"},{"sortkey":"*","hidden":"","*":"Chemicals_that_do_not_have_a_ChemSpider_ID_assigned"},{"sortkey":"*","hidden":"","*":"Chemical_articles_without_CAS_registry_number"},{"sortkey":"*","hidden":"","*":"Articles_without_EBI_source"},{"sortkey":"*","hidden":"","*":"Chemical_pages_without_DrugBank_identifier"},{"sortkey":"*","hidden":"","*":"Articles_without_KEGG_source"},{"sortkey":"*","hidden":"","*":"Articles_without_InChI_source"},{"sortkey":"*","hidden":"","*":"Articles_without_UNII_source"},{"sortkey":"Tgn1412","hidden":"","*":"Drugboxes_which_contain_changes_to_watched_fields"},{"sortkey":"W","hidden":"","*":"Drugs_that_are_a_monoclonal_antibody"},{"sortkey":"Tgn1412","hidden":"","*":"All_articles_with_unsourced_statements"},{"sortkey":"Tgn1412","hidden":"","*":"Articles_with_unsourced_statements_from_August_2011"},{"sortkey":"Tgn1412","hidden":"","*":"Articles_with_unsourced_statements_from_May_2016"},{"sortkey":"Tgn1412","hidden":"","*":"Articles_with_unsourced_statements_from_November_2017"},{"sortkey":"Tgn1412","hidden":"","*":"Use_dmy_dates_from_September_2010"},{"sortkey":"Tgn1412","*":"Monoclonal_antibodies"},{"sortkey":"Tgn1412","*":"Clinical_trial_disasters"},{"sortkey":"Tgn1412","*":"2006_in_London"},{"sortkey":"Tgn1412","*":"Experimental_drugs"},{"sortkey":"Tgn1412","*":"Abandoned_drugs"}],"links":[{"ns":0,"*":"Theralizumab (data page)"},{"ns":0,"exists":"","*":"Abrilumab"},{"ns":0,"exists":"","*":"Adalimumab"},{"ns":0,"exists":"","*":"Adverse effect (medicine)"},{"ns":0,"exists":"","*":"Afelimomab"},{"ns":0,"exists":"","*":"Agonist"},{"ns":0,"exists":"","*":"Anatomical Therapeutic Chemical Classification System"},{"ns":0,"exists":"","*":"Andecaliximab"},{"ns":0,"exists":"","*":"Angioedema"},{"ns":0,"exists":"","*":"Anifrolumab"},{"ns":0,"exists":"","*":"Anrukinzumab"},{"ns":0,"exists":"","*":"Antibody"},{"ns":0,"exists":"","*":"Antigen"},{"ns":0,"exists":"","*":"Apolizumab"},{"ns":0,"exists":"","*":"Aselizumab"},{"ns":0,"exists":"","*":"Atezolizumab"},{"ns":0,"exists":"","*":"Atorolimumab"},{"ns":0,"exists":"","*":"Avelumab"},{"ns":0,"exists":"","*":"B7 family"},{"ns":0,"exists":"","*":"BIA 10-2474"},{"ns":0,"exists":"","*":"B cell"},{"ns":0,"exists":"","*":"Bad Pharma"},{"ns":0,"exists":"","*":"Basiliximab"},{"ns":0,"exists":"","*":"Belimumab"},{"ns":0,"exists":"","*":"Ben Goldacre"},{"ns":0,"exists":"","*":"Benralizumab"},{"ns":0,"exists":"","*":"Bertilimumab"},{"ns":0,"exists":"","*":"Besilesomab"},{"ns":0,"exists":"","*":"Bleselumab"},{"ns":0,"exists":"","*":"Blood (journal)"},{"ns":0,"exists":"","*":"Boehringer-Ingelheim"},{"ns":0,"exists":"","*":"Brazikumab"},{"ns":0,"exists":"","*":"Briakinumab"},{"ns":0,"exists":"","*":"Brodalumab"},{"ns":0,"exists":"","*":"CD28"},{"ns":0,"exists":"","*":"Camidanlumab tesirine"},{"ns":0,"exists":"","*":"Canakinumab"},{"ns":0,"exists":"","*":"Carlumab"},{"ns":0,"exists":"","*":"Cedelizumab"},{"ns":0,"exists":"","*":"Cemiplimab"},{"ns":0,"exists":"","*":"Certolizumab pegol"},{"ns":0,"exists":"","*":"ChemSpider"},{"ns":0,"exists":"","*":"Chimeric antibody"},{"ns":0,"exists":"","*":"Chinese hamster ovary cell"},{"ns":0,"exists":"","*":"Chronic lymphocytic leukemia"},{"ns":0,"exists":"","*":"Clazakizumab"},{"ns":0,"exists":"","*":"Clenoliximab"},{"ns":0,"exists":"","*":"Clinical trial"},{"ns":0,"exists":"","*":"Clinical trial protocol"},{"ns":0,"exists":"","*":"Co-stimulation"},{"ns":0,"exists":"","*":"Complementarity determining region"},{"ns":0,"exists":"","*":"Corticosteroid"},{"ns":0,"exists":"","*":"Crab-eating Macaque"},{"ns":0,"exists":"","*":"Crizanlizumab"},{"ns":0,"exists":"","*":"Cytokine"},{"ns":0,"exists":"","*":"Cytokine release syndrome"},{"ns":0,"exists":"","*":"Daclizumab"},{"ns":0,"exists":"","*":"Digital object identifier"},{"ns":0,"exists":"","*":"Drug development"},{"ns":0,"exists":"","*":"Dupilumab"},{"ns":0,"exists":"","*":"Durvalumab"},{"ns":0,"exists":"","*":"Eculizumab"},{"ns":0,"exists":"","*":"Efalizumab"},{"ns":0,"exists":"","*":"Eldelumab"},{"ns":0,"exists":"","*":"Elsilimomab"},{"ns":0,"exists":"","*":"Emapalumab"},{"ns":0,"exists":"","*":"Enokizumab"},{"ns":0,"exists":"","*":"Eosinophil granulocyte"},{"ns":0,"exists":"","*":"Epratuzumab"},{"ns":0,"exists":"","*":"Erlizumab"},{"ns":0,"exists":"","*":"Etrolizumab"},{"ns":0,"exists":"","*":"EudraCT"},{"ns":0,"exists":"","*":"EudraVigilance"},{"ns":0,"exists":"","*":"European Medicines Agency"},{"ns":0,"exists":"","*":"Faralimomab"},{"ns":0,"exists":"","*":"Fezakinumab"},{"ns":0,"exists":"","*":"Fletikumab"},{"ns":0,"exists":"","*":"Fontolizumab"},{"ns":0,"exists":"","*":"Fresolimumab"},{"ns":0,"exists":"","*":"Galiximab"},{"ns":0,"exists":"","*":"Gavilimomab"},{"ns":0,"exists":"","*":"Gevokizumab"},{"ns":0,"exists":"","*":"Gilvetmab"},{"ns":0,"exists":"","*":"Gimsilumab"},{"ns":0,"exists":"","*":"Golimumab"},{"ns":0,"exists":"","*":"Gomiliximab"},{"ns":0,"exists":"","*":"Gordon Duff"},{"ns":0,"exists":"","*":"Guselkumab"},{"ns":0,"exists":"","*":"HIV"},{"ns":0,"exists":"","*":"Humanized"},{"ns":0,"exists":"","*":"Humanized antibody"},{"ns":0,"exists":"","*":"Ibalizumab"},{"ns":0,"exists":"","*":"Immune system"},{"ns":0,"exists":"","*":"Immunomodulator"},{"ns":0,"exists":"","*":"Immunosuppression"},{"ns":0,"exists":"","*":"In vitro"},{"ns":0,"exists":"","*":"In vivo"},{"ns":0,"exists":"","*":"Inebilizumab"},{"ns":0,"exists":"","*":"Infliximab"},{"ns":0,"exists":"","*":"Inolimomab"},{"ns":0,"exists":"","*":"Interleukin"},{"ns":0,"exists":"","*":"Intravenous"},{"ns":0,"exists":"","*":"Ipilimumab"},{"ns":0,"exists":"","*":"Itolizumab"},{"ns":0,"exists":"","*":"Ixekizumab"},{"ns":0,"exists":"","*":"Joseph Merrick"},{"ns":0,"exists":"","*":"Keliximab"},{"ns":0,"exists":"","*":"Lampalizumab"},{"ns":0,"exists":"","*":"Lanadelumab"},{"ns":0,"exists":"","*":"Lebrikizumab"},{"ns":0,"exists":"","*":"Lemalesomab"},{"ns":0,"exists":"","*":"Lenzilumab"},{"ns":0,"exists":"","*":"Lerdelimumab"},{"ns":0,"exists":"","*":"Lesion"},{"ns":0,"exists":"","*":"Letolizumab"},{"ns":0,"exists":"","*":"Ligelizumab"},{"ns":0,"exists":"","*":"Lirilumab"},{"ns":0,"exists":"","*":"List of withdrawn drugs"},{"ns":0,"exists":"","*":"Lokivetmab"},{"ns":0,"exists":"","*":"London"},{"ns":0,"exists":"","*":"Lulizumab pegol"},{"ns":0,"exists":"","*":"Lumiliximab"},{"ns":0,"exists":"","*":"Lymph node"},{"ns":0,"exists":"","*":"Macaca fascicularis"},{"ns":0,"exists":"","*":"Maslimomab"},{"ns":0,"exists":"","*":"Mavrilimumab"},{"ns":0,"exists":"","*":"Medicines and Healthcare products Regulatory Agency"},{"ns":0,"exists":"","*":"Memory T cell"},{"ns":0,"exists":"","*":"Mepolizumab"},{"ns":0,"exists":"","*":"Metelimumab"},{"ns":0,"exists":"","*":"Mirikizumab"},{"ns":0,"exists":"","*":"Mogamulizumab"},{"ns":0,"exists":"","*":"Monoclonal antibodies"},{"ns":0,"exists":"","*":"Monoclonal antibody"},{"ns":0,"exists":"","*":"Morolimumab"},{"ns":0,"exists":"","*":"Mouse"},{"ns":0,"exists":"","*":"Mucous membrane"},{"ns":0,"exists":"","*":"Multiple organ dysfunction syndrome"},{"ns":0,"exists":"","*":"Namilumab"},{"ns":0,"exists":"","*":"Natalizumab"},{"ns":0,"exists":"","*":"National Institute for Biological Standards and Control"},{"ns":0,"exists":"","*":"Nerelimomab"},{"ns":0,"exists":"","*":"New England Journal of Medicine"},{"ns":0,"exists":"","*":"New Scientist"},{"ns":0,"exists":"","*":"Nivolumab"},{"ns":0,"exists":"","*":"No-observed-adverse-effect level"},{"ns":0,"exists":"","*":"Northwick Park and St. Mark's Hospital"},{"ns":0,"exists":"","*":"Ocrelizumab"},{"ns":0,"exists":"","*":"Odulimomab"},{"ns":0,"exists":"","*":"Oleclumab"},{"ns":0,"exists":"","*":"Olokizumab"},{"ns":0,"exists":"","*":"Omalizumab"},{"ns":0,"exists":"","*":"Opsonisation"},{"ns":0,"exists":"","*":"Orphan drug"},{"ns":0,"exists":"","*":"Otelixizumab"},{"ns":0,"exists":"","*":"Oxelumab"},{"ns":0,"exists":"","*":"Ozoralizumab"},{"ns":0,"exists":"","*":"PAREXEL"},{"ns":0,"exists":"","*":"PRO 140"},{"ns":0,"exists":"","*":"Pamrevlumab"},{"ns":0,"exists":"","*":"Parexel"},{"ns":0,"exists":"","*":"Pascolizumab"},{"ns":0,"exists":"","*":"Pateclizumab"},{"ns":0,"exists":"","*":"Paul Ehrlich Institute"},{"ns":0,"exists":"","*":"Pembrolizumab"},{"ns":0,"exists":"","*":"Perakizumab"},{"ns":0,"exists":"","*":"Pexelizumab"},{"ns":0,"exists":"","*":"Phagocytosis"},{"ns":0,"exists":"","*":"Pharmacovigilance"},{"ns":0,"exists":"","*":"Phases of clinical research"},{"ns":0,"exists":"","*":"Pidilizumab"},{"ns":0,"exists":"","*":"Placebo"},{"ns":0,"exists":"","*":"Placebo-controlled studies"},{"ns":0,"exists":"","*":"Placulumab"},{"ns":0,"exists":"","*":"Plasma cell"},{"ns":0,"exists":"","*":"Plasmapheresis"},{"ns":0,"exists":"","*":"Plozalizumab"},{"ns":0,"exists":"","*":"Pre-clinical development"},{"ns":0,"exists":"","*":"Priliximab"},{"ns":0,"exists":"","*":"Primate"},{"ns":0,"exists":"","*":"PubMed Central"},{"ns":0,"exists":"","*":"PubMed Identifier"},{"ns":0,"exists":"","*":"Quilizumab"},{"ns":0,"exists":"","*":"Ravulizumab"},{"ns":0,"exists":"","*":"Regulation of therapeutic goods"},{"ns":0,"exists":"","*":"Regulatory T cell"},{"ns":0,"exists":"","*":"Reslizumab"},{"ns":0,"exists":"","*":"Rheumatoid arthritis"},{"ns":0,"exists":"","*":"Risankizumab"},{"ns":0,"exists":"","*":"Rontalizumab"},{"ns":0,"exists":"","*":"Route of administration"},{"ns":0,"exists":"","*":"Rovelizumab"},{"ns":0,"exists":"","*":"Ruplizumab"},{"ns":0,"exists":"","*":"Samalizumab"},{"ns":0,"exists":"","*":"Sarilumab"},{"ns":0,"exists":"","*":"Secretary of State for Health"},{"ns":0,"exists":"","*":"Secukinumab"},{"ns":0,"exists":"","*":"Sheffield University"},{"ns":0,"exists":"","*":"Sifalimumab"},{"ns":0,"exists":"","*":"Siplizumab"},{"ns":0,"exists":"","*":"Sirukumab"},{"ns":0,"exists":"","*":"Skin"},{"ns":0,"exists":"","*":"Statistics"},{"ns":0,"exists":"","*":"TGN1412"},{"ns":0,"exists":"","*":"T cell"},{"ns":0,"exists":"","*":"T cell receptor"},{"ns":0,"exists":"","*":"Tabalumab"},{"ns":0,"exists":"","*":"Talizumab"},{"ns":0,"exists":"","*":"Tavolimab"},{"ns":0,"exists":"","*":"TeGenero"},{"ns":0,"exists":"","*":"Technetium (99mTc) fanolesomab"},{"ns":0,"exists":"","*":"Technetium (99mTc) sulesomab"},{"ns":0,"exists":"","*":"Telimomab aritox"},{"ns":0,"exists":"","*":"Teneliximab"},{"ns":0,"exists":"","*":"Teplizumab"},{"ns":0,"exists":"","*":"Tezepelumab"},{"ns":0,"exists":"","*":"Tibulizumab"},{"ns":0,"exists":"","*":"Tildrakizumab"},{"ns":0,"exists":"","*":"Tislelizumab"},{"ns":0,"exists":"","*":"Tocilizumab"},{"ns":0,"exists":"","*":"Toralizumab"},{"ns":0,"exists":"","*":"Tralokinumab"},{"ns":0,"exists":"","*":"Tregalizumab"},{"ns":0,"exists":"","*":"Tremelimumab"},{"ns":0,"exists":"","*":"Ulocuplumab"},{"ns":0,"exists":"","*":"University of W\u00fcrzburg"},{"ns":0,"exists":"","*":"Urelumab"},{"ns":0,"exists":"","*":"Ustekinumab"},{"ns":0,"exists":"","*":"Vapaliximab"},{"ns":0,"exists":"","*":"Varlilumab"},{"ns":0,"exists":"","*":"Vatelizumab"},{"ns":0,"exists":"","*":"Vedolizumab"},{"ns":0,"exists":"","*":"Vepalimomab"},{"ns":0,"exists":"","*":"Veterinary medicine"},{"ns":0,"exists":"","*":"Visilizumab"},{"ns":0,"exists":"","*":"Vobarilizumab"},{"ns":0,"exists":"","*":"WHO Model List of Essential Medicines"},{"ns":0,"exists":"","*":"Zanolimumab"},{"ns":0,"exists":"","*":"Zolimomab aritox"},{"ns":0,"*":"TheraMAB"},{"ns":14,"exists":"","*":"Category:Articles with unsourced statements from August 2011"},{"ns":14,"exists":"","*":"Category:Articles with unsourced statements from May 2016"},{"ns":14,"exists":"","*":"Category:Articles with unsourced statements from November 2017"},{"ns":14,"exists":"","*":"Category:Use dmy dates from September 2010"},{"ns":14,"exists":"","*":"Category:CS1 maint: BOT: original-url status unknown"},{"ns":14,"exists":"","*":"Category:CS1 maint: Multiple names: authors list"},{"ns":6,"*":"File:Engineered monoclonal antibodies.svg"},{"ns":10,"exists":"","*":"Template:Monoclonals for immune system"},{"ns":4,"exists":"","*":"Wikipedia:Citation needed"},{"ns":11,"exists":"","*":"Template talk:Monoclonals for immune system"}],"templates":[{"ns":10,"exists":"","*":"Template:Drugbox"},{"ns":10,"exists":"","*":"Template:Infobox drug"},{"ns":10,"exists":"","*":"Template:Infobox"},{"ns":10,"exists":"","*":"Template:Infobox drug/title"},{"ns":10,"exists":"","*":"Template:Infobox drug/mab source"},{"ns":10,"exists":"","*":"Template:Infobox drug/licence"},{"ns":10,"exists":"","*":"Template:Infobox drug/pregnancy category"},{"ns":10,"exists":"","*":"Template:Unbulleted list"},{"ns":10,"exists":"","*":"Template:Infobox drug/formatATC"},{"ns":10,"exists":"","*":"Template:Main other"},{"ns":10,"exists":"","*":"Template:Infobox drug/legal status"},{"ns":10,"exists":"","*":"Template:Infobox drug/formatCASnumber"},{"ns":10,"exists":"","*":"Template:Infobox drug/formatPubChemCID"},{"ns":10,"exists":"","*":"Template:Infobox drug/formatPubChemSID"},{"ns":10,"exists":"","*":"Template:Infobox drug/formatIUPHARBPS"},{"ns":10,"exists":"","*":"Template:Infobox drug/formatDrugBank"},{"ns":10,"exists":"","*":"Template:Infobox drug/formatChemSpider"},{"ns":10,"exists":"","*":"Template:Infobox drug/formatUNII"},{"ns":10,"exists":"","*":"Template:Infobox drug/formatKEGG"},{"ns":10,"exists":"","*":"Template:Infobox drug/formatChEBI"},{"ns":10,"exists":"","*":"Template:Infobox drug/formatChEMBL"},{"ns":10,"exists":"","*":"Template:Infobox drug/formatChemDBNIAID"},{"ns":10,"exists":"","*":"Template:Infobox drug/formatPDBligand"},{"ns":10,"exists":"","*":"Template:Infobox drug/chemical formula"},{"ns":10,"exists":"","*":"Template:Chembox Elements/molecular formula"},{"ns":10,"exists":"","*":"Template:Chem molar mass"},{"ns":10,"exists":"","*":"Template:Chem molar mass/format"},{"ns":10,"exists":"","*":"Template:Yesno"},{"ns":10,"exists":"","*":"Template:Infobox drug/formatJmol"},{"ns":10,"exists":"","*":"Template:Nobold"},{"ns":10,"exists":"","*":"Template:Template other"},{"ns":10,"exists":"","*":"Template:Button"},{"ns":10,"exists":"","*":"Template:Border-radius"},{"ns":10,"exists":"","*":"Template:Linear-gradient"},{"ns":10,"exists":"","*":"Template:Infobox drug/maintenance categories"},{"ns":10,"exists":"","*":"Template:Citation needed"},{"ns":10,"exists":"","*":"Template:Fix"},{"ns":10,"exists":"","*":"Template:Category handler"},{"ns":10,"exists":"","*":"Template:Fix/category"},{"ns":10,"exists":"","*":"Template:Delink"},{"ns":10,"exists":"","*":"Template:Col-begin"},{"ns":10,"exists":"","*":"Template:Col-break"},{"ns":10,"exists":"","*":"Template:Col-end"},{"ns":10,"exists":"","*":"Template:Reflist"},{"ns":10,"exists":"","*":"Template:Column-width"},{"ns":10,"exists":"","*":"Template:Cite web"},{"ns":10,"exists":"","*":"Template:Cite journal"},{"ns":10,"exists":"","*":"Template:Cite news"},{"ns":10,"exists":"","*":"Template:Cite press release"},{"ns":10,"exists":"","*":"Template:Doi"},{"ns":10,"exists":"","*":"Template:Hide in print"},{"ns":10,"exists":"","*":"Template:Str left"},{"ns":10,"exists":"","*":"Template:Only in print"},{"ns":10,"exists":"","*":"Template:Subscription"},{"ns":10,"exists":"","*":"Template:Subscription required"},{"ns":10,"exists":"","*":"Template:Link note"},{"ns":10,"exists":"","*":"Template:PMID"},{"ns":10,"exists":"","*":"Template:Catalog lookup link"},{"ns":10,"exists":"","*":"Template:Trim"},{"ns":10,"exists":"","*":"Template:Yesno-no"},{"ns":10,"exists":"","*":"Template:PMC"},{"ns":10,"exists":"","*":"Template:Monoclonals for immune system"},{"ns":10,"exists":"","*":"Template:Navbox"},{"ns":10,"exists":"","*":"Template:PharmNavFootnote"},{"ns":10,"exists":"","*":"Template:Use dmy dates"},{"ns":10,"exists":"","*":"Template:DMCA"},{"ns":10,"exists":"","*":"Template:Dated maintenance category"},{"ns":10,"exists":"","*":"Template:FULLROOTPAGENAME"},{"ns":10,"exists":"","*":"Template:Ns has subpages"},{"ns":828,"exists":"","*":"Module:Infobox"},{"ns":828,"exists":"","*":"Module:Navbar"},{"ns":828,"exists":"","*":"Module:InfoboxImage"},{"ns":828,"exists":"","*":"Module:List"},{"ns":828,"exists":"","*":"Module:TableTools"},{"ns":828,"exists":"","*":"Module:Arguments"},{"ns":828,"exists":"","*":"Module:String"},{"ns":828,"exists":"","*":"Module:TemplatePar"},{"ns":828,"exists":"","*":"Module:ParameterCount"},{"ns":828,"exists":"","*":"Module:Yesno"},{"ns":828,"exists":"","*":"Module:Unsubst"},{"ns":828,"exists":"","*":"Module:Category handler"},{"ns":828,"exists":"","*":"Module:Category handler/data"},{"ns":828,"exists":"","*":"Module:Category handler/config"},{"ns":828,"exists":"","*":"Module:Category handler/shared"},{"ns":828,"exists":"","*":"Module:Category handler/blacklist"},{"ns":828,"exists":"","*":"Module:Namespace detect/data"},{"ns":828,"exists":"","*":"Module:Namespace detect/config"},{"ns":828,"exists":"","*":"Module:Delink"},{"ns":828,"exists":"","*":"Module:No globals"},{"ns":828,"exists":"","*":"Module:Citation/CS1"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Configuration"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Whitelist"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Utilities"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Date validation"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Identifiers"},{"ns":828,"exists":"","*":"Module:Citation/CS1/COinS"},{"ns":828,"exists":"","*":"Module:Check for unknown parameters"},{"ns":828,"exists":"","*":"Module:Navbox"},{"ns":828,"exists":"","*":"Module:Ns has subpages"}],"images":["Lock-green.svg","T_cell_activation.svg","CD28_structure.gif"],"externallinks":["https://web.archive.org/web/20060412052458/http://www.tegenero.com/research__development/drug_development/index.php","http://www.tegenero.com/research__development/drug_development/index.php","http://meeting.bloodjournal.org/cgi/content/abstract/104/11/2519","https://www.newscientist.com/article/dn9734-mystery-over-drug-trial-debacle-deepens/","https://www.telegraph.co.uk/news/uknews/1540591/Study-claims-to-solve-drug-trial-mystery.html","http://bloodjournal.hematologylibrary.org/cgi/content/full/109/7/2968%7C","//doi.org/10.1182/blood-2006-10-050724","//www.ncbi.nlm.nih.gov/pubmed/17119120","https://web.archive.org/web/20060319033931/http://www.tegenero.com/documents/pr_tegenero_march_11_2005.pdf","http://www.tegenero.com/documents/pr_tegenero_march_11_2005.pdf","https://web.archive.org/web/20060318205642/http://tegenero.com/documents/2003_11_tg005_pressrelease_e.pdf","http://www.tegenero.com/documents/2003_11_tg005_pressrelease_e.pdf","http://www.circare.org/foia5/tgn1412investigatorbrochure.pdf","//www.ncbi.nlm.nih.gov/pmc/articles/PMC2193880","//doi.org/10.1084/jem.20021024","//www.ncbi.nlm.nih.gov/pubmed/12707299","//www.ncbi.nlm.nih.gov/pmc/articles/PMC1868523","//doi.org/10.1016/j.clim.2006.10.014","http://www.jem.org/cgi/content/full/190/4/487","http://www.jleukbio.org/cgi/content/abstract/72/4/769","https://web.archive.org/web/20070821215621/http://www.mhra.gov.uk/home/idcplg?IdcService=GET_FILE&dDocName=CON2023519&RevisionSelectionMethod=LatestReleased","http://www.mhra.gov.uk/home/idcplg?IdcService=GET_FILE&dDocName=CON2023519&RevisionSelectionMethod=LatestReleased","//www.ncbi.nlm.nih.gov/pmc/articles/PMC1905242","//doi.org/10.1046/j.1365-2249.1999.00848.x","http://www.parexel.com/news_and_events/press_releasesSingle.asp?id=233","http://content.nejm.org/cgi/content/full/355/10/1018","http://news.bbc.co.uk/1/hi/england/london/4820188.stm","http://www.nwlh.nhs.uk/news/item.cfm?id=97","http://news.ft.com/cms/s/0a2ebf2a-b529-11da-aa90-0000779e2340.html","https://web.archive.org/web/20051231104428/http://today.reuters.co.uk/news/newsArticle.aspx?type=topNews","http://today.reuters.co.uk/news/newsArticle.aspx?type=topNews&storyID=2006-03-19T143944Z_01_L19788458_RTRUKOC_0_UK-BRITAIN-TRIAL-EXPERT.xml&archived=False","//doi.org/10.1016/j.jaci.2008.07.049","https://www.newscientist.com/article/dn8863-catastrophic-immune-response-may-have-caused-drug-trial-horror.html","https://www.telegraph.co.uk/news/main.jhtml?xml=/news/2006/03/17/ntrial117.xml&sSheet=/news/2006/03/17/ixhome.html","http://news.bbc.co.uk/1/hi/england/london/4823992.stm","https://web.archive.org/web/20060521150601/http://www.tegenero.com/news/faqs_re_tgn1412/index.php","http://www.tegenero.com/news/faqs_re_tgn1412/index.php","http://www.nature.com/news/2006/060313/full/060313-17.html","https://web.archive.org/web/20120105003015/http://www.rss.org.uk/site/cms/contentviewarticle.asp?article=523","http://www.rss.org.uk/site/cms/contentviewarticle.asp?article=523","//www.ncbi.nlm.nih.gov/pmc/articles/PMC4594046","//doi.org/10.1017/S0963180115000079","//www.ncbi.nlm.nih.gov/pubmed/26364776","http://webarchive.nationalarchives.gov.uk/20141205150130/http://www.mhra.gov.uk/NewsCentre/Pressreleases/CON2023515","http://www.mhra.gov.uk/NewsCentre/Pressreleases/CON2023515","http://webarchive.nationalarchives.gov.uk/20141206051830/http://www.mhra.gov.uk/NewsCentre/Pressreleases/CON2023822","http://webarchive.nationalarchives.gov.uk/20110505014645/http://www.mhra.gov.uk/home/idcplg?IdcService=GET_FILE&dDocName=CON2023519&RevisionSelectionMethod=LatestReleased","http://webarchive.nationalarchives.gov.uk/20130107105354/http://dh.gov.uk/en/publicationsandstatistics/publications/publicationspolicyandguidance/dh_063117","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1702450/","https://doi.org/10.1136%2Fbmj.39062.336157.DB","https://www.ncbi.nlm.nih.gov/pubmed/17256444","https://doi.org/10.1016%2Fj.copbio.2009.10.002","//www.ncbi.nlm.nih.gov/pubmed/19892543","https://doi.org/10.1111%2Fj.1476-5381.2010.00922.x","//www.ncbi.nlm.nih.gov/pubmed/20880392","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2990151/","http://www.tandfonline.com/doi/full/10.3109/1547691X.2012.711783After","https://doi.org/10.3109%2F1547691X.2012.711783","//www.ncbi.nlm.nih.gov/pubmed/22967038","https://www.reuters.com/article/us-drug-comeback-exclusive/exclusive-drug-that-caused-elephant-man-side-effect-makes-comeback-after-2006-disaster-idUSKBN0MK1SQ20150324","https://clinicaltrials.gov/ct2/show/study/NCT01990157","https://www.telegraph.co.uk/finance/personalfinance/11089564/Would-you-accept-3750-to-trial-one-drug.html","https://dx.doi.org/10.1038/440855a","http://news.bbc.co.uk/1/hi/health/4914546.stm","http://news.bbc.co.uk/1/hi/health/5015224.stm","http://briandeer.com/tgn1412/dispatches.htm","http://www.nature.com/news/2007/070122/full/070122-10.html","http://rosettapr.com/perspectives.php","http://bmj.bmjjournals.com/cgi/content/full/333/7562/270"],"sections":[{"toclevel":1,"level":"2","line":"Description of the drug","number":"1","index":"1","fromtitle":"Theralizumab","byteoffset":6927,"anchor":"Description_of_the_drug"},{"toclevel":1,"level":"2","line":"Mechanism of action","number":"2","index":"2","fromtitle":"Theralizumab","byteoffset":8457,"anchor":"Mechanism_of_action"},{"toclevel":1,"level":"2","line":"Clinical trials","number":"3","index":"3","fromtitle":"Theralizumab","byteoffset":13884,"anchor":"Clinical_trials"},{"toclevel":1,"level":"2","line":"Criticism and controversy","number":"4","index":"4","fromtitle":"Theralizumab","byteoffset":22790,"anchor":"Criticism_and_controversy"},{"toclevel":1,"level":"2","line":"Medicines and Healthcare products Regulatory Agency view","number":"5","index":"5","fromtitle":"Theralizumab","byteoffset":27314,"anchor":"Medicines_and_Healthcare_products_Regulatory_Agency_view"},{"toclevel":1,"level":"2","line":"Follow up publications","number":"6","index":"6","fromtitle":"Theralizumab","byteoffset":31142,"anchor":"Follow_up_publications"},{"toclevel":1,"level":"2","line":"See also","number":"7","index":"7","fromtitle":"Theralizumab","byteoffset":33829,"anchor":"See_also"},{"toclevel":1,"level":"2","line":"References","number":"8","index":"8","fromtitle":"Theralizumab","byteoffset":34097,"anchor":"References"},{"toclevel":1,"level":"2","line":"External links","number":"9","index":"9","fromtitle":"Theralizumab","byteoffset":34322,"anchor":"External_links"}],"parsewarnings":[],"displaytitle":"Theralizumab","iwlinks":[],"properties":[{"name":"defaultsort","*":"Tgn1412"},{"name":"wikibase_item","*":"Q424452"}]}}